

# BIOLOGY AND MANAGEMENT OF PANCREATIC CANCER

Paula Ghaneh, Eithne Costello, John P Neoptolemos

1134

*Gut* 2007;56:1134–1152. doi: 10.1136/gut.2006.103333

**P**ancreatic cancer continues to pose an enormous challenge to clinicians and cancer scientists. With a more affluent world the global incidence of pancreatic cancer is rising. For the first time significant advances are now being made into the management of the disease. There is a more sophisticated approach to palliative care and the centralisation of pancreatic cancer services is leading to greater tumour resection rates. Newer adjuvant modalities are also greatly increasing the 5 year survival rates. The molecular basis of pancreatic cancer is now better understood than ever before, leading to the development of new diagnostic approaches and the introduction of mechanistic based treatments. Technical advances in imaging and great improvements in conventional and molecular pathology have led to a deeper understanding of the pathological variables of the disease. This is now an important time for making big inroads into what still remains the most lethal of the common cancers.

Pancreatic ductal adenocarcinoma remains one of the most difficult cancers to treat. It is the commonest cancer affecting the exocrine pancreas. In 2000, there were 217 000 new cases of pancreatic cancer and 213 000 deaths world wide and in Europe 60 139 new patients (10.4% of all digestive tract cancers) and 64 801 deaths.<sup>1</sup> In 2002 there were 7152 new cases in the UK, with similar numbers in men and women.<sup>2</sup> In the USA in 2006 there were 33 730 new cases and 32 300 deaths.<sup>3</sup> Without active treatment, metastatic pancreatic cancer has a median survival of 3–5 months and 6–10 months for locally advanced disease, which increases to around 11–15 months with resectional surgery.<sup>4</sup> The late presentation and aggressive tumour biology of this disease mean that only a minority (10–15%) of patients can undergo potentially curative surgery. Major advances in the past decade have included improvements in operative mortality and morbidity through the development of specialist regional centres and improved survival using systemic chemotherapy.<sup>4–5</sup> Significant progress has been made in unravelling risk factors and key molecular events in pancreatic carcinogenesis, leading to potentially exciting new developments in diagnosis, screening of high-risk groups and mechanistic based treatments (MBTs).

## MOLECULAR PATHOGENESIS AND THERAPEUTIC TARGETS IN PANCREATIC CANCER

### Pancreatic precursor lesions

The ductal phenotype gives rise to three distinct cancer precursor lesions with distinct, although overlapping, gene alterations: mucinous cystic neoplasms, intraductal papillary mucinous neoplasms (IPMNs) and pancreatic intraepithelial neoplasia (PanINs) (box 1).<sup>6</sup> PanINs are classified into early and late lesions, starting with PanIN-1A, 1B (hyperplasia) and progressing to PanIN-2 and then to PanIN-3 or carcinoma in situ (fig 1).<sup>7–9</sup>

### Alterations in oncogenic molecular pathways

#### K-ras

Activating mutations in K-ras, mostly codon 12 but also affecting codons 13 or 61, occur in 75–90% of pancreatic cancers.<sup>10–11</sup> Ras is a 21 kDa membrane-bound GTP-binding protein involved in growth factor-mediated signal transduction pathways. The mutations result in a constitutively activated form of Ras in which the protein is locked in the GTP-bound state, capable of stimulating a multitude of downstream signalling cascades.<sup>12</sup> K-ras mutations are often found in benign lesions of the pancreas<sup>13–15</sup> as well as in early precursor lesions.<sup>6</sup> Post-translational modification of Ras protein involves farnesylation of the C terminus, mediated by farnesyl transferase and is a major therapeutic target (fig 2),<sup>16–17</sup> although farnesyl transferase inhibitors up to now have not been successful in phase III trials.<sup>18</sup>

Alternative approaches that directly target K-ras are now available in the form of RNA interference<sup>19</sup> and are showing promise both alone<sup>20</sup> and in conjunction with radiation.<sup>21</sup> Signalling pathways, downstream of Ras also offer therapeutic targets such as the Raf-MEK ERK

See end of article for authors' affiliations

Correspondence to:  
Professor J P Neoptolemos,  
School of Cancer Studies,  
Division of Surgery and  
Oncology, University of  
Liverpool, 5th Floor UCD  
Building, Daulby Street,  
Liverpool L69 3GA, UK; j.p.  
neoptolemos@liverpool.ac.uk

**Box 1 Molecular pathogenesis and drug development**

- ▶ Precursor lesions PanIN 1–3 associated with specific molecular alterations.
- ▶ Around 100 mechanistic based treatments are in early clinical trial development and there are number of large phase III trials are in progress.
- ▶ Developmental signalling pathways such as notch/hedgehog are currently undergoing further investigation.
- ▶ Relevant transgenic animal models are now available for molecular analysis and therapeutic studies.
- ▶ Immunotherapies and vaccination treatments are now receiving intense evaluation.

pathway. Sorafenib, an inhibitor of Raf-1 kinase and vascular endothelial growth factor receptor-2 is now an FDA approved drug for the treatment of renal cell carcinoma,<sup>22</sup> but despite being well tolerated, it is inactive in patients with advanced pancreatic cancer.<sup>23</sup>


**Growth factors and their receptors**

The epidermal growth factor receptor (EGFR, also known as human EGF receptor 1 or HER 1) is a major therapeutic target for pancreatic cancer. EGFR is a transmembrane glycoprotein that consists of an extracellular ligand-binding domain with cysteine-rich regions, a hydrophobic transmembrane domain, and an intracellular tyrosine kinase domain. It is a member of the ErbB family of receptor tyrosine kinases, which includes EGFR (EGFR-1), ErbB-2 (HER-2), ErbB-3, and ErbB-4. Of these, EGFR-1, ErbB-2 and ErbB-3 have all been shown to be overexpressed in pancreatic cancer.<sup>24–26</sup> The principal natural ligands for EGFR-1, epidermal growth factor (EGF) and


transforming growth factor- $\alpha$  (TGF- $\alpha$ ) are also overexpressed in this disease.<sup>24–27</sup> By binding ligands to the extracellular domain, the EGFR causes receptor homodimerisation or heterodimerisation (with other ErbB family members). This in turn leads to phosphorylation of tyrosine residues on the intracellular domain. The phosphorylated residues then provide docking sites for intracellular mediators which activate downstream signalling pathways (fig 2), including the Ras-Raf-MEK signalling pathway (transmitting growth signals), the PI3K/Akt signalling pathway (mediates cell cycle progression and survival) and the signal transducer and activator of transcription (STAT) family of proteins (mediates a variety of features conducive to cancer cell survival progression, including cell division, motility, invasion and adhesion).<sup>28</sup>

Cetuximab is a chimeric monoclonal antibody that binds to the extracellular domain of EGFR, promoting receptor internalisation and subsequent degradation without receptor phosphorylation and activation. This diminishes the available receptor for natural ligand binding and prevents activation of EGFR-associated, downstream signalling pathways.<sup>28</sup> The first clinical trial in patients with advanced pancreatic cancer tested the combination of cetuximab and gemcitabine and showed an encouraging 1-year survival rate of 32% in a phase II trial<sup>29</sup> and has led to the SWOG S0502 phase III trial (target 704 patients), which has completed recruitment and is due to report.<sup>30</sup>

Erlotinib (Tarceva) is an orally active small molecule that binds to the ATP binding site on the intracellular kinase domain, thus inhibiting the tyrosine kinase activity of the receptor. A recent phase III trial (569 patients) tested erlotinib in combination with gemcitabine for advanced pancreatic cancer.<sup>31</sup> Overall survival was significantly better in the erlotinib arm than in the placebo controlled arm, with a median survival of 6.4 vs 5.9 months ( $p = 0.025$ ) (hazard ratio = 0.81, 95% CI



**Figure 1** Histological images of benign pancreatic ductal epithelial cells, progressive PanIN lesions and invasive carcinoma, with associated genetic alterations.



**Figure 2** Schematic representation of molecular oncogenic signalling pathways in pancreatic cancer. Agents targeting specific aspects of these pathways are indicated in blue boxes.

0.67 to 0.97) and 1-year survival of 24% vs 17%, respectively, the benefit mostly restricted to patients developing a distinctive rash. Erlotinib was approved by the United States FDA in 2005, but European registration is restricted to patients with metastatic disease and does not include those with locally advanced cancer.

High levels of a number of other growth factor receptors and their ligands are also expressed in pancreatic cancer and/or PanIN lesions and represent alternative targets. These include insulin-like growth factor (IGF) and its tyrosine kinase receptor, insulin growth factor receptor 1 (IGF-1R), members of the fibroblast growth factor family, the Met receptor tyrosine kinase and its ligand HGF/scatter factor and vascular endothelial growth factor (VEGF) receptors and ligands.<sup>32</sup> VEGF promotes endothelial cell growth and survival, thus enhancing angiogenesis. VEGF expression occurs in 90% of pancreatic cancers, correlates with microvessel density and in moderate/high levels with reduced survival.<sup>33</sup> Bevacizumab (Avastin), an anti-VEGF monoclonal antibody, showed promise in combination with gemcitabine, in a phase II trial of advanced pancreatic cancer,<sup>34</sup> but the CALGB 80303 phase III trial was unsuccessful<sup>35</sup> and the Avita trial, which included treatment with gemcitabine plus erlotinib with and without bevacizumab, has been closed. Multitargeted tyrosine kinase inhibitors such as, ZD6474, a dual epidermal growth factor receptor and VEGF receptor 2 small-molecule tyrosine kinase inhibitor, and sunitinib a VEGF receptor 1, 2 and 3, c-KIT, and platelet-derived growth factor receptor  $\alpha$  and  $\beta$  tyrosine kinase inhibitor hold promise for pancreatic cancer treatment.<sup>36</sup>

### PI3K/Akt signalling pathway


The lipid kinase phosphoinositide 3-OH kinase (PI3K)/Akt pathway (fig 2) regulates cell survival, proliferation, and

resistance to apoptosis. The Akt2 gene was shown to be amplified or activated in up to 60% of pancreatic carcinomas.<sup>37–40</sup> Akt mediates the inhibition of pro-apoptotic proteins BAD and caspase 9. Downstream of Akt, the mammalian target of rapamycin (mTOR) promotes cell survival and proliferation<sup>41</sup> by modulating cellular signals in response to mitogenic stimuli and various nutrients, especially amino acids. The mTOR–S6K1 signalling pathway is essential for proliferation of pancreatic cancer cells in vitro,<sup>42–44</sup> and the mTOR inhibitor, CCI-779, which demonstrates antitumour activity,<sup>45</sup> is under investigation in early-phase trials for pancreatic cancer. Akt also activates the transcription factor nuclear factor kappa B (NF $\kappa$ B), which promotes survival and resistance to chemotherapy.<sup>46</sup> Bortezomib, a proteasome inhibitor that functions, at least in part, by stabilising the I $\kappa$ B $\alpha$  protein and inhibiting NF $\kappa$ B activation, is currently undergoing phase I evaluation for pancreatic cancer treatment.<sup>47</sup>

### Alterations in molecular pathways affecting tumour suppressor genes

#### p16INK4A/retinoblastoma (Rb) protein pathway

The activation of cyclin-dependent kinases (CDKs), initially in response to mitogenic signals (cyclin D-dependent kinases) and subsequently in a mitogenic-independent manner (cyclin E-dependent kinases), leads to the sequential phosphorylation of Rb, facilitating the transcription of E2F-regulated genes and consequent entry into the S-phase (fig 3).<sup>48–49</sup> The INK4A gene product, p16INK4A, interferes with this process by binding to CDK4/CDK6, preventing the formation of active cyclin D-CDK4/CDK6 complexes. As a result, phosphorylation of Rb is suppressed, blocking entry into the S-phase. In pancreatic cancer the pRb/p16 tumour suppressor pathway appears to be



**Figure 3** Mitogenic signals give rise to increased levels of cyclin D and the consequent formation of active cyclin D/ cyclin-dependent kinase 4 or 6 (CDK4/ CDK6) complexes leads to the phosphorylation of retinoblastoma (Rb), facilitating the transcription of E2F-regulated genes (including cyclin E) required for the S-phase. Cyclin E-CDK2 complexes further phosphorylate Rb. The tumour suppressor INK4A gene product interferes with this process by binding to CDK4/CDK6, thus preventing the formation of active cyclin D-CDK4/CDK6 complexes. The tumour suppressor, p53, is activated in response to DNA damage or other cellular stresses. MDM2 is a p53-inducible gene, the protein product of which keeps p53 levels low. The p14ARF protein inhibits MDM2, thus inducing p53. Activated p53 either initiates Rb-dependent cell cycle arrest by inducing the transcription of p21<sup>CIP1</sup>, which inhibits cyclin E-CDK2, or leads to apoptosis.

abrogated, most commonly through functional inactivation of the INK4A gene. Loss of p16INK4A function occurs in 80–95% of pancreatic cancers.<sup>50–52</sup>

While p16INK4A inhibits cell proliferation by activating Rb, p19ARF (a gene overlapping with p16) accomplishes the same end through activation of p53 by inhibiting its MDM2-dependent proteolysis, although ARF may possess additional p53-independent functions.<sup>53–54</sup> Around 40% of pancreatic cancers lose both the INK4A and ARF transcripts, mutations may occur in the p16 gene but not in the ARF gene, suggesting that INK4A loss alone may be a major event in the development of pancreatic cancer.<sup>55</sup>

**Transcription factor p53**

More than 50% of pancreatic cancer cases have mutations in the TP53 gene.<sup>50</sup> The p53 transcription factor is normally maintained at very low levels as a result of interaction with the oncoprotein HDM2 (the human homologue of MDM2), which

targets p53 for proteosomal degradation. Under conditions of cellular stress, such as genotoxic damage or oncogene activation, the HDM2-p53 interaction is inhibited, and the p53 protein is stabilised. The levels of p53 thus increase and it regulates a transcription response leading to cell cycle arrest or to apoptosis (fig 3).<sup>48</sup> After oncogene-mediated activation, p14ARF protein inhibits MDM2, leading to the stabilisation and thus activation of p53. A recent study found that ARF was crucial for tumour suppression, while the DNA damage-induced p53 response was dispensable.<sup>56</sup>

**Smad4/TGF-β pathway**

Smad4, was originally isolated as a tumour suppressor gene for pancreatic cancer. Although Smad4 mutations are not particularly common in cancer, in general, pancreatic cancer is characterised by a high degree of alteration in the MADH4 locus on chromosome 18 (18q21.1) that encodes Smad4. It undergoes loss of heterozygosity in ~90% of pancreatic cancers,

**Table 1** Hereditary cancer syndromes affecting the pancreas

| Syndrome  | Gene mutation                        | Pancreatic cancer lifetime risk                    |
|---|--------------------------------------|--|
| Familial pancreatic cancer <sup>101</sup>                   | BRCA2 in up to 20%                   | Variable dependent on pedigree—up to 50%           |
| Family X <sup>102</sup>                                     | Palladin                             | Family X affected subjects carry the P239S variant |
| FAMMM—pancreatic cancer variant <sup>109</sup>              | TP16                                 | 17% (p16 Leiden mutation)                          |
| Familial breast and ovarian cancer syndromes <sup>110</sup> | BRCA1 and BRCA2                      | Pedigree dependent                                 |
| Fanconi anaemia <sup>111</sup>                              | FANCA, B, C, D1 (BRCA2), D2, E, F, G | ? ~5% (patients <50 years may carry genes)         |
| Peutz-Jeghers syndrome <sup>112</sup>                       | STK11/LKB1                           | 36%  |
| Hereditary pancreatitis <sup>93</sup>                       | PRSS1 in up to 80%                   | 35%  |
| von Hippel-Lindau disease <sup>113</sup>                    | VHL                                  | ? ~5% (neuroendocrine tumours are frequent)        |
| Ataxia telangiectasia <sup>114</sup>                        | ATM                                  | ? – unusual (breast cancer is most common)         |
| Li-Fraumeni syndrome <sup>115</sup>                         | TP53                                 | ~5%  |
| Cystic fibrosis <sup>116</sup>                              | CFTR                                 | ? ~ 5% (increased risk of digestive track cancers) |
| FAP <sup>117–118</sup>                                      | APC                                  | ?  |
| HNPCC <sup>119</sup>  | MLH1, MSH2, MSH6, PMS1, PMS2         | ? ~5%  |

FAMMM, familial atypical multiple mole melanoma; FAP, familial adenomatous polyposis; HNPCC, hereditary non-polyposis colon cancer.

and around 50% of cases have completely lost functional Smad4 protein.<sup>57–58</sup> The loss of Smad4 has important effects on the tumour microenvironment and potentiation of invasion.<sup>59–61</sup>

The Smad4 protein is a member of the Smad family of transcription factors and has a pivotal role in mediating signal transmission of members of the TGF- $\beta$  superfamily of cytokines.<sup>62</sup> TGF- $\beta$  ligands and TGF- $\beta$  receptors have been found to be highly expressed in pancreatic cancer.<sup>32–63</sup> TGF- $\beta$  ligands are potent regulators of cancer cell growth, differentiation and migration. Knockdown of Smad4 was shown to lead to TGF- $\beta$ -induced cell cycle arrest and migration but not to TGF- $\beta$ -induced epithelial–mesenchymal transition,<sup>64</sup> indicating that loss of Smad4 seemed to abolish TGF- $\beta$ -mediated tumour suppressive functions, while maintaining at least some TGF- $\beta$ -mediated tumour promoting functions. TGF- $\beta$ -based therapeutic strategies in cancer are in development.<sup>62</sup>

### Reactivation of developmental signalling in pancreatic cancer

#### Notch

The Notch pathway has an important role in directing decisions about the fate of cells in the developing pancreas and in pancreatic cancer initiation and invasion.<sup>65–66</sup> This pathway comprises cell surface-expressed notch receptors which are activated by a number of transmembrane ligands, including Delta, Serrate, and Lag-2 of the delta and jagged families expressed on neighbouring cells, thus mediating communication between adjacent cells expressing the receptors and ligands. This signalling pathway is important for the processes of apoptosis, differentiation and proliferation. Activation leads to proteolytic intramembrane cleavage of Notch receptors, releasing their active intracellular domain, which translocates to the nucleus and binds to the transcription factor CSL (RBP-J $\kappa$ /CBF in mammals; Suppressor of Hairless (Su(H) in *Drosophila*) inducing the transcription of a variety of target genes including the hairy enhancer of split (HES) family of transcriptional repressors. HES family members act to maintain cells in a precursor state. The pathway is active during embryogenesis, but not in the pancreas, while upregulation of a number of Notch target genes occurs in pre-neoplastic lesions and in invasive pancreatic cancer.<sup>67</sup> Notch signalling promotes vascularisation in tumours<sup>68</sup> and is a clear target for new drug development.

#### Hedgehog

Hedgehog signalling has a major role in the initiation and growth of pancreatic cancer.<sup>69–73</sup> There are three Hedgehog family members or ligands, sonic hedgehog, Indian hedgehog and desert hedgehog, which are crucial for the development of the gastrointestinal tract. Together with the transmembrane proteins Smoothed and Patched, these signalling proteins/ligands closely coordinate organ development, as well as a variety of functions in adult tissues. Cyclopamine inhibits the Hedgehog pathway through direct interaction with Smoothed<sup>65–74–75</sup> and has now entered early clinical trial development.

Sonic hedgehog may also be a feature of so called pancreatic cancer stem cells.<sup>76</sup> The existence of cancer stem cells is based on the hypothesis that the ability of a tumour to grow and propagate is dependent on a small subset of cells (<5%) with special properties, which like normal stem cells, have a great

potential for self-renewal and production of differentiated progeny.<sup>77</sup> After a report that a clone of a distinct CD44<sup>+</sup>CD24<sup>-</sup> epithelial-specific antigen (ESA)<sup>+</sup> could initiate human metastatic breast cancer in immunodeficient non-obese diabetic/severe combined immunodeficient mice, Li *et al* have recently identified a CD44<sup>+</sup>CD24<sup>+</sup>ESA<sup>+</sup> phenotype (0.2–0.8%) isolated from primary pancreatic cancer cells with a 100-fold increased tumourigenic potential.<sup>76</sup> Increased numbers of cells, however, were needed to generate tumours when injected into the pancreas compared with the subcutaneum.

### The pancreatic tumour microenvironment

In considering the biology of any cancer, the interplay between cancer cells and the surrounding supporting host cells, known as tumour stroma, cannot be ignored. This interplay has effects on blood vessel formation, invasion, metastasis and evasion of the host immune system.<sup>78</sup> Pancreatic cancer has a particularly intense desmoplastic stroma, which can account for a large proportion of the pancreatic tumour volume. It comprises extracellular matrix, together with a number of different host cell types, including fibroblasts, small endothelial-lined vessels, residual normal epithelia and a variety of inflammatory cells, which are both locally derived and recruited from the circulation. The biology of the pancreatic tumour microenvironment is being actively researched,<sup>79</sup> not least, because it is a potential therapeutic site, such as for antiangiogenic strategies, as discussed above. Targeting stromal matrix, in the form of matrix metalloproteinase (MMP) inhibitors either with or without gemcitabine, has failed to improve patients' outcome.<sup>80–81</sup> This might be due to the fact that there are many closely related MMPs, and current MMP inhibitors lack sufficient specificity.<sup>82</sup>

### Lessons from animal models

Comprehension of transcription factor activity in the developing pancreas and elucidation of the sequence of genetic alteration in pancreatic cancer development, have been greatly advanced by the development of new genetically engineered animal models of pancreatic cancer.<sup>83–84</sup> Targeted expression of oncogenic KRAS to pancreatic progenitor cells in mice resulted in the generation of progressive PanIN lesions, followed by low-frequency progression to invasive and metastatic adenocarcinoma.<sup>85</sup> The development of pancreatic cancer was remarkably accelerated by the inclusion of mutations in INK4A/ARF or TP53.<sup>86</sup> Thus it appears that activated KRAS serves to initiate PanIN formation while INK4A/ARF tumour suppressors limit the malignant conversion of these PanINs to ductal adenocarcinoma. Similarly, the concomitant expression of oncogenic

#### Box 2 Risk factors for pancreatic cancer

- ▶ Increasing age
- ▶ Tobacco smoking
- ▶ Inherited predisposition: at least two other family members affected
- ▶ Hereditary pancreatitis
- ▶ Chronic pancreatitis
- ▶ Cancer family syndromes
- ▶ Late-onset diabetes mellitus without diabetes risk factors
- ▶ Increased body mass index

**Table 2** Histological variants of malignant tumours of the exocrine pancreas<sup>125–131</sup>

| Histological type <sup>125</sup>                                   | Frequency (%) | Comment  |
|--|---------------|--|
| <i>Ductal adenocarcinoma</i> <sup>125 126</sup>                    | 80            | Long-term survival rare  |
| Ductal adenocarcinoma variants                                     |               |  |
| Undifferentiated (anaplastic) carcinoma                            | 5             | Worse prognosis than ductal                                    |
| Mucinous non-cystic  | 2             | Poor prognosis   |
| Adenosquamous  | 2             | Poor prognosis   |
| Mucinous non-cystic carcinoma                                      | <1            | Poor prognosis   |
| Signet-ring cell carcinoma   | <1            | Poor prognosis   |
| Adenosquamous carcinoma  | <1            | More aggressive than ductal                                    |
| Mixed ductal–endocrine carcinoma                                   | <1            | Poor prognosis   |
| Osteoclast-like giant cell tumour                                  | <1            | Poor prognosis   |
| <i>Other malignancies</i> <sup>125 127 128</sup>                   |               |  |
| Serous cystadenocarcinoma  | <1            | Prognosis similar to ductal                                    |
| Mucinous cystadenocarcinoma  | 3             | Prognosis similar to ductal                                    |
| Intraductal papillary-mucinous neoplasm— <i>invasive carcinoma</i> | 1–3           | High proportion of patients present with preinvasive lesions   |
| Acinar cell carcinoma <sup>125 129</sup>                           | 2             | Variable prognosis   |
| Acinar cell cystadenocarcinoma                                     | –             | –  |
| Mixed acinar–endocrine carcinoma                                   | –             | –  |
| Pseudopapillary carcinoma <sup>125 130</sup>                       | <1            | Tends to occur in women—more favourable prognosis              |
| Pancreatoblastoma <sup>125 131</sup>                               | Rare          | Childhood and adolescent tumour with relatively good prognosis |

KRAS and mutant p53 in the mouse pancreas led to accelerated metastatic pancreatic cancer development compared with that seen with oncogenic KRAS alone.<sup>85 86</sup> Mutant p53 alone did not induce a cancer phenotype.<sup>86</sup>

### Immunotherapy and vaccines

The limits of conventional cytotoxic drugs in pancreatic cancer have been the main driver for the development of MBTs. In parallel with this has been an explosion of preclinical development of immunotherapies, including cancer vaccination in pancreatic cancer, but the clinical results so far have proved rather disappointing.<sup>87</sup> Telomerase overexpression occurs early in the development of pancreatic cancer and can be targeted by telomerase vaccines such as GV1001, with promising phase II results.<sup>88</sup> These have now led to the development of a large phase III trial (TeloVac) trial that is exploring the role of simultaneous or sequential cytotoxic and vaccine treatment in advance pancreatic cancer.

### AETIOLOGY AND SECONDARY SCREENING

The biggest risk factors for pancreatic cancer are increasing age, smoking,<sup>89</sup> new onset diabetes mellitus,<sup>90</sup> increased body mass index,<sup>89</sup> chronic pancreatitis,<sup>91 92</sup> hereditary pancreatitis<sup>93</sup> and an inherited predisposition for pancreatic cancer (box 2).<sup>94 95</sup> A variety of dietary factors are also associated with an increased risk of pancreatic cancer, all of which are amenable to intervention and comprise increased red and processed meat consumption<sup>96</sup> and reduced intake of methionine<sup>97</sup> and folate from food sources.<sup>98</sup>

Tobacco smoking is associated with a twofold increase and because of the prevalence may account for around 30% of all cases with pancreatic ductal adenocarcinoma. Chronic pancreatitis is now recognised as a risk factor, with some series finding a 15–25-fold risk.<sup>91 92</sup> It has been observed that patients may have chronic pancreatitis for at least 20 years before the

development of pancreatic cancer. These patients tend to have severe disease, increased calcification of the gland and a higher rate of complications. The risk of developing cancer is even higher with hereditary pancreatitis, with estimates of a 70-fold increase in risk.<sup>93</sup> This is an uncommon disorder inherited as an autosomal dominant condition with an estimated 80% penetrance and an equal gender incidence, presenting in children and younger adults. The gene responsible was identified as the PRSS1 gene, and mutations have a causative role, resulting in a gain of function of the digestive enzyme trypsin.

There is an inherited component to pancreatic cancer accounting for about 10% of observed cases.<sup>94 95</sup> Familial pancreatic cancer itself is rare and the European Registry of Hereditary Pancreatitis and Familial Pancreatic Cancer (EUROPAC) (<http://www.liv.ac.uk/surgery/europac.html>, accessed 22 May 2007) has been established to provide a database of these families for long-term follow-up, with the aim of identifying people at risk and developing a screening programme in the future. Diagnostic criteria are two or more first-degree relatives with pancreatic ductal adenocarcinoma or two or more second-degree relatives with pancreatic cancer, one of whom has early-onset pancreatic cancer (age <50 years at diagnosis). Overall, the observed to expected rate of pancreatic cancer is significantly raised by ninefold, rising specifically from fourfold in families with one first-degree relative, to 6.4-fold where there are two affected relatives to 32.0-fold with three relatives with pancreatic cancer.<sup>95</sup>

There is evidence that familial pancreatic cancer is an autosomal dominant condition<sup>99</sup> and appears to demonstrate the phenomenon of anticipation with the age of onset reducing in succeeding generations.<sup>100</sup> The main gene and causative mutation have not yet been identified, although up to 20% of families with familial pancreatic cancer have a BRCA2 mutation.<sup>101</sup> One candidate gene is palladin,<sup>102</sup> which encodes a component of the cytoskeleton that controls cell shape and

motility, and has been identified in the susceptibility locus 4q32–34 in a large family from Seattle, USA (called family X),<sup>103</sup> but both the susceptibility locus and the palladin gene variant described have not been confirmed in EUROPAC families.<sup>104–105</sup>

Several studies have examined the association between genetic polymorphisms and pancreatic cancer.<sup>94</sup> Although over the whole population none of the genetic polymorphisms for two carcinogen-metabolising enzymes (cytochrome P450 1A1 (CYP1A1) and glutathione S-transferase (GST)) could be directly associated with the risk of pancreatic cancer, the combination of heavy smoking and a deletion polymorphism in GSTT1 was associated with an increased risk of pancreatic cancer among Caucasians.<sup>106</sup> Polymorphisms of glutathione S-transferase M1 (GSTM1) and acetyltransferases (NAT1 and NAT2) enzymes may also be associated with a modest increase in susceptibility to pancreatic cancer and chronic pancreatitis.<sup>107</sup> The UDP glucuronosyltransferase (UGT1A7) gene is predominantly expressed in the human pancreas. The low detoxification activity UGT1A7\*3 allele has been identified as a new risk factor of pancreatic diseases, defining an interaction of genetic predisposition and environmentally induced oxidative injury.<sup>108</sup>

Several inherited cancer syndromes are associated with pancreatic cancer (table 1).<sup>94–101–102–109–119</sup> The highest risk of pancreatic cancer in all of these cancer syndromes is in Peutz–Jeghers syndrome with a 120-fold lifetime risk and a 36% cumulative lifetime risk.<sup>112</sup> Although responsible for this syndrome, germline mutations of the STK11/LKB1 gene are not involved in familial pancreatic cancer.<sup>120</sup> Pancreatic cancer is the second most common cancer in the familial atypical multiple mole melanoma syndrome and is particularly significant in patients and families with the p16 Leiden mutation.<sup>109</sup> Pancreatic cancer is also seen in some families with breast cancer and BRCA1 and BRCA2 mutations.<sup>110</sup> The cumulative risk of pancreas cancer to age 75–years in BRCA2 carriers is 7%, and BRCA2 may account for as many as 5% of all cases of pancreatic cancer.<sup>94</sup> It is evident that a number of these genes act as modifier genes on environmental and other genetic risk factors. RNASEL (encoding ribonuclease L) gene variants/mutations (Glu265X and Arg462Gln) implicated in sporadic and familial prostate cancer may also contribute to the tumorigenesis of sporadic and familial pancreatic cancer but do not directly cause pancreatic cancer.<sup>121</sup>

Patients at high risk warrant screening,<sup>122–124</sup> but these programmes have not been adequately assessed and at the present time secondary screening (box 3) should only be undertaken as part of an investigational study such as that organised by EUROPAC.<sup>122–123</sup>

### Box 3 Secondary screening

- ▶ All patients with an increased inherited risk of pancreatic cancer should be referred to a specialist centre offering clinical advice and genetic counselling and, where appropriate, genetic testing such as for BRCA2 mutations.
- ▶ Primary screening for pancreatic cancer in the general population is not feasible at present.
- ▶ Secondary screening for pancreatic cancer in high-risk cases should only be part of an investigational programme.

## PATHOLOGY, STAGING AND RESECTION MARGINS (BOX 4)

Ductal adenocarcinoma is the most common malignant tumour of the pancreas (table 2).<sup>125–131</sup> Characteristically, there is an intense desmoplastic reaction in the stroma surrounding these tumours. Sixty-five per cent are located within the head, 15% in the body, 10% in the tail and 10% are multifocal. Tumours of the head of the pancreas tend to present earlier with obstructive jaundice or acute pancreatitis. Tumours of the body and tail tend to present late and are associated with a worse prognosis. There are guidelines for minimum data set reporting and staging.<sup>132–133</sup> Pancreatic ductal adenocarcinoma must be distinguished from carcinomas of the intrapancreatic bile duct, ampulla of Vater or duodenal mucosa as these tumours have a much better prognosis. In about 20% of cases it is not possible to distinguish the tissue of origin of cancers arising in the head of the pancreas, and the term “peri-ampullary cancer” is often applied. Application of chip-based DNA expression techniques will hopefully overcome this problem with the spread of molecular pathology complementing traditional histology, as even intrapancreatic bile duct cancers have genetic similarities to pancreatic ductal adenocarcinomas.<sup>134</sup>

The key factors relating to prognosis are tumour grade and diameter and lymph node status. The microscopic resection margin status is also an important survival factor, although less so within the adjuvant context.<sup>135</sup> A positive microscopic resection margin (R1) is operationally defined as at least one cancer cell within 1 mm of any surface of the resected specimen. A positive R1 margin is unrelated to tumour diameter but rather to histological grade and lymph node status, indicating that this has more to do with the biology of the tumour than with physical factors.<sup>136</sup>

## DIAGNOSIS

Advances in technology have meant that the sensitivity for detecting smaller lesions is improving, as is the identification of extrapancreatic spread (box 5).<sup>137–139</sup>

### Tumour markers and proteomic signatures

The most commonly used marker in everyday practice CA19-9 has a sensitivity of 70–90% and specificity of 90%, and is better than other markers, including CA-50 and DU-PAN-2 and CEA.<sup>140</sup> False positive results are often obtained in benign obstructive jaundice, chronic pancreatitis even in the absence of bile duct obstruction and ascites. CA19-9 is particularly useful in assessing response to prognosis and treatment in advanced cases, identifying early recurrence in resected cases and as an aid in preoperative staging.<sup>140–142</sup> New markers, including HCGβ,<sup>143</sup> CA72-4,<sup>143</sup> osteopontin,<sup>144</sup> REG4,<sup>145</sup> RCAS1<sup>146</sup> and MIC-1<sup>147</sup> are under evaluation, but radically newer approaches that hold real promise are new proteomic techniques identifying unique panels of proteins associated with pancreatic cancer and protein profiles providing a distinctive pancreatic signature.<sup>148–150</sup> Gene expression profiling may also help to categorise prognostic groups.<sup>134</sup>

### Non-invasive imaging techniques

Transabdominal ultrasound can be the initial investigation and may detect tumours >2 cm in size, dilatation of the biliary and main pancreatic ducts and possible extrapancreatic spread— notably, liver metastases, with a diagnostic accuracy of 75%,<sup>151</sup>

#### Box 4 Pathological typing, staging and resection margins

- ▶ Most pancreatic cancers are pancreatic ductal adenocarcinomas.
- ▶ Accurate pathological typing and staging is essential to determine the most appropriate treatment and prognostic groups.
- ▶ In 20% of cases it is not possible to distinguish the tissue of origin of pancreatic cancers: "peri-ampullary cancer".
- ▶ Chip-based technologies will lead to a more accurate typing of tissue origin.
- ▶ Resection margin status needs to be clearly defined. At present, a tumour <1 mm from the margin is reported as positive.

but it is not useful in early disease, if the bile duct is not dilated and in obese patients. Therefore contrast-enhanced multidetector CT scan is the single most useful imaging procedure (using a pancreas protocol CT with 1 mm images) and can achieve diagnostic rates of 97% for pancreatic cancer.<sup>152</sup> The accuracy for predicting an unresectable lesion is 90%, but the accuracy of predicting a resectable lesion is much less at 80–85%<sup>139 152 153</sup> (figs 4–7). False negative results before laparotomy are mainly due to small hepatic metastases <1 cm and small peritoneal deposits. Lymph node staging is inaccurate in the absence of systematic biopsy.<sup>154</sup>

Magnetic resonance imaging produces similar results to contrast-enhanced multislice CT and is useful for patients who cannot receive intravenous contrast.<sup>155 156</sup> Positron emission tomography (PET) cannot differentiate inflammatory conditions from tumours accurately and the sensitivity is 71–87% with specificity of around 64–80%.<sup>157</sup> The use of fusion CT-PET scanning adds little if anything to the use of CT alone.<sup>158</sup> Measurement of tumour metabolism by nuclear magnetic spectroscopy holds considerable promise as a diagnostic technique but is very much in development.<sup>159</sup>

#### Invasive imaging techniques

Endoluminal ultrasonography (EUS) has similar accuracy to CT in the staging of pancreatic cancer but is undoubtedly better for the detection of early pancreatic tumours as small as 2–3 mm<sup>139</sup> (fig 8). The addition of fine needle aspiration (FNA) cytology to EUS is highly accurate for identifying malignancy in lesions identified on EUS and not seen on CT scan.<sup>139 160</sup> The drawbacks of EUS are that distant metastases and nodal involvement cannot be accurately assessed. The sensitivity and specificity of endoscopic retrograde cholangiopancreatography (ERCP) alone are 70–82% and 88–94%, respectively, in symptomatic patients or those with suspected pancreatic cancer but should no longer be used as a pure imaging tool given the developments in magnetic resonance cholangiopancreatography and EUS.<sup>139 140 155 156 160</sup> ERCP is used to insert biliary stents for relief of obstructive jaundice<sup>161</sup> and to gain cytological diagnosis by sampling or brushings. These can also be obtained at percutaneous transhepatic cholangiography (PTHC).<sup>140</sup>

#### Diagnostic biopsy

Percutaneous FNA cytology has a sensitivity and specificity of 69% and 100%, respectively, for tissue diagnosis,<sup>140</sup> but concerns


#### Box 5 Diagnosis

- ▶ The use of contrast-enhanced multidetector CT is the preferred method for non-invasive staging of pancreatic cancer.
- ▶ Other modalities such as magnetic resonance cholangiopancreatography and endoluminal ultrasonography may contribute further information but should only be used selectively.
- ▶ Preoperative endoscopic retrograde cholangiopancreatography brushing for cytology should be undertaken in all cases undergoing endoscopic stenting.
- ▶ Laparoscopy with laparoscopic ultrasound may be appropriate in selective cases to improve staging.
- ▶ Tissue diagnosis should be sought in all cases deemed unresectable.
- ▶ Transperitoneal techniques of tissue biopsy have relatively poor sensitivity and should be avoided in cases where resection is possible.

have remained about intraperitoneal seeding, with an incidence of up to 16%.<sup>162</sup> The diagnostic accuracy of EUS with FNA carries a sensitivity and specificity of >90% and ~100%, respectively, but requires an expert team with the presence of a cytologist examining the tissue specimens in the EUS suite, repeating the procedure until the diagnosis is conclusive.<sup>163</sup> The incidence of carcinomatosis is much less after EUS-guided biopsy than percutaneous biopsy.<sup>164</sup> A further development is the use of EUS with an endoscopic trucut biopsy needle.<sup>165</sup> EUS-guided biopsy is thus the preferred procedure if histological confirmation is needed in cases of advanced pancreatic cancer before chemotherapy or to diagnose small uncharacterised lesions.


#### Laparoscopy and laparoscopic ultrasound

Laparoscopy with laparoscopic ultrasound enables intraoperative scanning of the liver and pancreas to be performed and is highly predictive of resectability, altering the management of 15% of patients already assessed as resectable by dual-phase helical CT.<sup>166</sup> Selective laparoscopy based on the serum level of CA19-9 is a more efficient strategy, reducing the proportion of patients undergoing laparoscopic ultrasound from 100% to around 45% while increasing the yield from 15% to 25%.<sup>167</sup>



**Figure 4** Contrast-enhanced multidetector CT scan image of a resectable pancreatic adenocarcinoma with acceptable planes of cleavage between the tumour (t) and the superior mesenteric vein (arrow) and the superior mesenteric artery (arrowhead).





**Figure 5** Contrast-enhanced multidetector CT scan image of pancreatic tumour encasing the hepatic artery (arrow) and obliteration of the portal vein (cross) causing cavernous transformation. This patient is unresectable.

### CYSTIC TUMOURS

Pancreatic cystic neoplasms are being increasingly identified with the wider employment of high-quality abdominal imaging and comprise at least 15% of all pancreatic cystic masses (box 6).<sup>125 168 169</sup> The three most common primary pancreatic cystic neoplasms are serous cystic neoplasm, mucinous cystic neoplasm and intraductal papillary mucinous neoplasm (IPMN). Serous cystic neoplasms predominantly affect women, are found mostly in the head of pancreas and represent 30% of primary cystic neoplasms. Mucinous cystic neoplasms also are found more often in women, but mostly in the body and tail of the pancreas, and represent 40% of primary cystic neoplasms. Unlike IPMNs the cyst does not communicate with the main pancreatic duct. IPMNs tend to affect more men than women, can involve a part or the whole of the pancreatic ductal system, affect older patients and represent 30% of primary pancreatic cysts.<sup>125 168 169</sup>

### Pathology

Serous cystic neoplasms consist of a well-demarcated spongy, honeycomb mass with small cysts lined by a simple cuboidal epithelium with glycogen-rich cytoplasm (fig 9) and rarely progress to serous cystadenocarcinoma. Mucinous cystic neoplasms consist of a larger often solitary cyst to begin with and may have a septum or septae contained within the cyst lined by simple mucinous columnar epithelium and there is a characteristic ovarian-type stroma (fig 10). IPMNs are classified as arising either from the main duct (fig 11) or branch duct (fig 12) and can be mixed. They are characterised by intraductal proliferation of neoplastic mucinous cells forming papillae and excessive mucous secretion. These changes lead to dilatation of the main pancreatic duct or branch duct.<sup>169 170</sup> IPMNs arising in the branch ducts are less aggressive than those arising in the main duct, which have a high incidence of malignant lesions.<sup>171 172</sup> There is a greatly increased risk of colorectal cancer and other extrapancreatic cancers in patients with IPMN.<sup>173 174</sup> There is also an increased risk of developing other cancers of the pancreas.<sup>175</sup>

### Diagnosis

Serous cystic neoplasms may be polycystic or honeycomb as on cross-sectional imaging with a central scar (fig 9), and are sometimes calcified but may also appear to be solid. Mucinous



**Figure 6** Contrast-enhanced multidetector CT scan image of pancreatic tumour encasing the superior mesenteric artery (arrow). This patient has unresectable disease.

cystic neoplasms may have thick irregular walls with papillary invaginations (fig 12) and sometimes peripheral calcification. The characteristic radiological feature of IPMN is side-branch cystic dilatation in communicating with the main pancreatic duct or dilatation of the main pancreatic duct (figs 11 and 13) full of mucous readily seen at endoscopy or dilatation; malignant potential may be related to size ( $\geq 3$  cm) and mural nodules.<sup>172</sup> Early lesions may be evaluated by intraductal pancreatoscopy and intraductal ultrasonography.<sup>169</sup> Fluid by FNA from serous cystic neoplasms lacks mucin. The cyst fluid from mucinous cystic neoplasms is viscous and will stain positive for mucin with high levels of CEA or CA19-9.<sup>169</sup>

### Management options

If a lesion can be positively identified as a serous cystic neoplasm then a conservative approach with regular follow-up imaging is justified, particularly if the patient is frail or elderly.<sup>169 175</sup> Mucinous cystic neoplasms should be resected if the patient is fit for major surgery owing to the high malignant potential. All main duct IPMNs should be resected if the patient is fit, combined with frozen section assessment of the main pancreatic duct resection margin; the patient should be prepared to undergo a total pancreatectomy. Patients with relatively benign features of branch duct IPMN (diameter  $< 3.5$  cm, absence of nodules and thick walls, CA 19-9  $< 25$  kU/l, absence of recent-onset or worsened diabetes, absence of jaundice or of any other symptom) may be managed with



**Figure 7** Coronal section of multidetector CT scan demonstrating pancreatic tumour encasing the portal vein. This patient has unresectable disease.

### Box 6 Cystic tumours of the pancreas

- ▶ Most non-inflammatory pancreatic cysts are malignant or premalignant: main differential diagnosis is a pancreatic pseudocyst.
- ▶ The three main types are serous cystic neoplasms, mucinous cystic neoplasms and intraductal papillary mucinous neoplasms (IPMN).
- ▶ Patients with pancreatic cysts have an increased risk of developing other cancers of the pancreas and also extrapancreatic cancers such as colorectal cancer.
- ▶ Mainstays of diagnosis are CT scan, magnetic resonance cholangiopancreatography and endoluminal ultrasonography with fine needle aspiration and cyst fluid analysis (cytology, mucin, CEA and Ca19-9).
- ▶ Serous cystadenomas are nearly always benign and may be managed conservatively and kept under radiological surveillance.
- ▶ Side-branch IPMNs that lack malignant features may also be managed conservatively with radiological monitoring: diameter <3.5 cm, absence of nodules and thick walls, CA19-9 <25 kU/l, absence of recent-onset or worsened diabetes, absence of jaundice or of any other symptom.
- ▶ Resection is needed for all mucinous cystic neoplasms and main duct IPMN.

regular follow-up imaging instead of resection in certain patients.<sup>176</sup>

### TREATMENT OF PANCREATIC CANCERS Inoperable disease

The treatment of patients who have localised advanced disease, metastases or performance status is directed at symptom control (box 7).

#### Pain


Intractable pain is a major problem and often necessitates the use of high-dose opiate analgesia. Complementary approaches include intraoperative, percutaneous CT-guided or EUS neurolytic coeliac plexus block<sup>140 177–179</sup> and bilateral or unilateral thoracoscopic splanchnicectomy.<sup>180</sup> In general, the results are disappointing and are particularly poor for patients with tumours in the body and tail of the pancreas. Pain control with coeliac plexus block was improved in a randomised study compared with systemic analgesia, but this was not reflected in the quality of life or survival.<sup>178</sup>

#### Weight loss

Weight loss initially is due to pancreatic exocrine insufficiency owing to obstruction of the main pancreatic duct as well as exclusion of bile acids from obstruction of the main bile duct. Fat maldigestion may also contribute to abdominal pain and bloating. Relief of biliary obstruction and pancreatic enzyme supplementation will alleviate these symptoms.<sup>181</sup> Cachexia can be a marked feature of the later stages of pancreatic cancer, with no good treatment.

#### Biliary and duodenal obstruction

Biliary stenting using ERCP is the preferred option with the combined PTHC-endoscopy approach employed only if the former is technically not possible.<sup>140</sup> The life of a plastic stent is about 3 months, causing recurrent jaundice. Self-expanding




**Figure 8** Endoluminal ultrasound demonstrating a small pancreatic cancer.

metal (and covered) stents have greatly reduced the risk of obstruction and acute cholangitis. Metal stents should be used for patients with a good performance status and favourable prognosis (locally advanced primary tumour <3 cm) and plastic ones for those patients with metastases and tumours  $\geq 3$  cm in diameter.<sup>182</sup> Expandable metal stents are being increasingly deployed endoscopically for duodenal obstruction (occurs in ~15%), with a technical success rate of around 85%, but may be associated with serious complications, including perforation, fistula and bleeding and recurrent obstruction due to stent migration or fracture.<sup>183</sup> Surgical bypass (open and laparoscopic) can be used to relieve jaundice using a Roux-en-Y loop hepatojejunostomy, and duodenal obstruction by gastrojejunostomy, especially in younger patients and both can be achieved laparoscopically.<sup>184 185</sup>

#### Chemotherapy

Pancreatic ductal adenocarcinoma is highly resistant to conventional methods of cytotoxic treatment and radiotherapy (box 8).<sup>186–189</sup> Few chemotherapeutic agents have been shown to



**Figure 9** (A) Contrast-enhanced multidetector CT scan image of a serous cystic neoplasm, demonstrating the characteristic honeycomb appearance. (B) Honeycomb cysts of serous cystic neoplasm are lined by simple cuboidal epithelium with (glycogen-rich) clear cell cytoplasm.

### Box 7 Symptom control in advanced pancreatic cancer

1144


- ▶ The main analgesic method is the use of modern oral opiate preparations; neurolytic coeliac plexus block should be considered as complementary in selected cases.
- ▶ Pancreatic enzyme supplements should be used to maintain weight and increase quality of life.
- ▶ Endoscopic biliary stenting should be used in malignant biliary obstruction.
- ▶ Metal stents should be used in patients with defined parameters (locally advanced tumour <3 cm diameter), plastic stents should be used otherwise.
- ▶ Younger patients with relatively good performance status may undergo biliary drainage—in which case they should also undergo prophylactic gastrojejunostomy to prevent late gastric outlet obstruction (occurs in around 15%).
- ▶ Duodenal and gastric outlet obstruction may also be treated endoscopically.

have reproducible response rates of more than 10%. 5-Fluorouracil (5FU) is an inhibitor of thymidylate synthetase (essential for synthesis of DNA nucleotides) and has been the most widely used in advanced pancreatic cancer, with a median survival of around 5–6 months and is better than the best supportive care.<sup>186–189</sup> A pivotal trial in 1997 meant that the nucleoside analogue, gemcitabine, replaced 5FU as the preferred drug.<sup>190</sup> Although the median survival improvement in favour of gemcitabine compared with 5FU was slight (5.7 vs 4.4 months), the 1-year survival rate was more encouraging (18% vs 2%), and most importantly, the toxicity was relatively mild and achieved a better clinical response (24% vs 5%, respectively).<sup>190</sup>

Capecitabine (Xeloda) is a new oral, fluoropyrimidine carbamate that is sequentially converted to 5FU by three enzymes located in the liver and in tumours, including pancreatic cancer. The Cancer Research UK GemCap trial comparing gemcitabine alone or in combination with capecitabine demonstrated significantly improved survival with this combination than with gemcitabine alone<sup>191</sup> and is supported by other studies.<sup>189, 192–194</sup> A recent meta-analysis has demonstrated that combination gemcitabine chemotherapy is better than gemcitabine alone; the best combinations may be with capecitabine or platinum-based agents, allowing for acceptable levels of toxicity of the combinations.<sup>189</sup>

#### Chemoradiotherapy and follow-on chemotherapy

Radiotherapy has been widely used for the treatment of pancreatic cancer.<sup>187, 188</sup> The main drawback is the limit on the dosage owing to the close proximity of adjacent radiosensitive organs. External beam radiotherapy is routinely used with 5FU as a radiosensitising agent (chemoradiotherapy), although gemcitabine is now being evaluated as an alternative radiosensitiser. Newer techniques such as conformal radiotherapy are now being used, but these studies almost invariably employ follow-on chemotherapy once the chemoradiotherapy has been completed. A recent meta-analysis demonstrated that chemoradiotherapy is better than radiotherapy alone and that there is no survival difference between chemoradiotherapy plus follow-on chemotherapy and chemotherapy alone.<sup>188</sup> A recent phase III study compared chemoradiotherapy and follow-on gemcitabine



**Figure 10** (A) Endoluminal ultrasonography showing septate mucinous cystic lesion. (B) Simple columnar mucinous epithelial lining of a mucinous cystic neoplasm.

with gemcitabine alone in patients with locally advanced disease.<sup>195</sup> The trial was closed prematurely because of significant toxicity in the combination arm and significantly reduced median survival in the combination arm (8.4 vs 14.3 months;  $p = 0.014$ ).

#### Newer agents

A number of new agents and MBTs have been developed from the molecular understanding of pancreatic cancer, which are now being assessed in large phase III trials in advanced pancreatic cancer (table 3).<sup>196–201</sup>

#### Resectable disease

##### Selection and staging

Once the pancreatic cancer has been identified, the patient needs to be assessed for fitness for major surgery and the



**Figure 11** (A) Contrast-enhanced multidetector CT scan image of a main duct intraductal papillary mucinous neoplasm, demonstrating dilatation of the whole of the main pancreatic duct. (B) High-power view of intraductal papillary mucinous neoplasm, showing minimal atypia within the lining mucinous epithelium.

**Box 8 Palliative therapy in advanced pancreatic cancer**

- ▶ Chemotherapy will improve survival and quality of life in patients with advanced pancreatic cancer.
- ▶ Chemoradiotherapy and follow-on chemotherapy are no better than chemotherapy alone.
- ▶ The best chemotherapy combination available at the present time is gemcitabine combined with either capecitabine or a platinum agent with acceptable toxicity.
- ▶ Where possible, patients with advanced pancreatic cancer should be offered treatment with new therapeutic drugs as part of an early drug development programme or as part of a phase III randomised controlled clinical trial.
- ▶ New agents will be expensive but will become increasingly targeted based on molecular profiling.

tumour staged preoperatively for resectability (box 9 and table 4). Venous resection is necessary during the course of a pancreatectomy in 5–10% of patients. Vascular reconstruction in this context results in a median and long-term survival that is similar to that of patients not needing a venous reconstruction.<sup>202</sup> It should be emphasised, however, that routine venous resection in patients with significant venous involvement is not feasible and the results of arterial reconstruction are unacceptably poor.<sup>203</sup> The resection rates and short- and long-term results are significantly better in high-volume centres, and major pancreas cancer surgery should only be undertaken in regional and supraregional centres.<sup>204–207</sup>

**Surgical techniques**

Preoperative endoscopic stenting does not influence surgical outcome, but it may facilitate logistical planning of staging and treatment.<sup>161 204 208</sup> Metal stents should be avoided in patients who have tumours that may be resectable because of the tissue reaction they invoke, although resection is still technically possible. The aim of surgery is to achieve an R0 resection: complete clearance of macroscopic tumour with clear microscopic resection margins, even if there are lymph node metastases. In practical terms a large proportion of patients (at least 35%) are histologically staged as R1: complete clearance of macroscopic tumour with positive resection margins.<sup>204</sup> R2 resections result in incomplete resection of macroscopic tumour and should be treated in the same category as patients with locally advanced pancreatic cancer as they have an equally poor prognosis. Resecting these patients may lead to longer survival than chemoradiotherapy.<sup>209</sup>

The standard operation for tumours of the head of the pancreas is the Kausch–Whipple partial pancreateoduodenectomy (KW-PPD).<sup>210</sup> There are various methods of reconstruction involving the pancreatic anastomosis. The benefit from a pancreatogastrostomy rather than a pancreatojejunostomy is still unclear,<sup>211</sup> and there may be no advantage for the routine use of pancreatic stents.<sup>212</sup> The pylorus-preserving partial pancreateoduodenectomy (PP-PPD) is the most commonly used resection approach, which despite being a smaller procedure is as effective as a KW-PPD (table 5).<sup>213–215</sup> Patients with tumours of the pancreatic body or tail undergo left pancreatectomy usually with en bloc resection of the spleen and hilar lymph nodes.<sup>204</sup> There is no role for total pancreatectomy unless this is


**Box 9 Surgery in pancreatic cancer**

- ▶ Surgical resection should be confined to specialist centres; increased resection rates and survival and decreased hospital costs, morbidity and mortality.
- ▶ Endoscopic biliary drainage before surgery does not influence surgical outcome but may assist with logistical planning.
- ▶ Pancreatoduodenectomy with or without pylorus preservation is the most appropriate procedure.
- ▶ Portal vein resections are needed in about 10% of resections but should not be performed routinely.
- ▶ Arterial reconstruction cannot be supported except in exceptional circumstances.
- ▶ Extended radical resections should not be undertaken because of increased mortality and morbidity and reduced quality of life.
- ▶ Use of prophylactic somatostatin analogues reduces post-operative morbidity.


the only means by which an R0 resection can be achieved.<sup>204</sup> Extended radical lymphadenectomy is associated with significantly increased morbidity without any survival benefit and is now rejected for routine practice.<sup>216–218</sup> Involvement of para-aortic lymph nodes (Japanese Pancreas Society Lymph Node Station 16b1) is not a contraindication to resection and should probably be included as part of the routine resection procedure.<sup>219</sup> Postoperative morbidity remains high at around 40% even in supraregional units.<sup>207</sup> Independent risk factors are age >70 years, extended resections and main pancreatic duct diameter <3 mm.<sup>220</sup> Postoperative complications may be reduced by the prophylactic use of octreotide.<sup>221</sup>

**Adjuvant treatment**

Radical resection alone will result in a 5-year survival of only 10% owing to recurrence after surgery.<sup>204</sup> Nearly all patients develop metastatic disease, most commonly of the liver and peritoneum but also the lungs, and this may occur with or without local recurrence.<sup>187 204 222</sup> Although chemoradiation to the area of the resection may reduce the local failure rate, survival length is the same as with systemic chemotherapy.<sup>187</sup> After pancreatic resection, the most important independent prognostic markers are lymph node status, tumour size and tumour grade.<sup>135 136</sup> The results from two large randomised trials show that adjuvant systemic chemotherapy will increase the 5-year survival from 9% to 12% with resection alone to 21–29%



**Figure 12** Contrast-enhanced multidetector CT scan image of a mucinous cystic neoplasm, demonstrating a papillary invagination.



**Figure 13** (A) Magnetic resonance imaging scan demonstrating a side-branch intraductal papillary mucinous neoplasm. (B) Low-power view of branch-type intraductal papillary mucinous neoplasm, showing papillary infoldings of lining epithelium.

and 23% with either 5FU and folinic acid or gemcitabine, respectively (box 10).<sup>223–225</sup> Table 6 summarises all the randomised trials of adjuvant systemic chemotherapy.<sup>168–173</sup> The ESPAC-3(v2) trial comparing adjuvant gemcitabine and 5FU has closed to recruitment with 1030 patients, with 2-year survival as the end point. The survival benefit of adjuvant chemotherapy is maintained irrespective of the type of operation used and whether or not patients develop post-operative complications.<sup>229</sup>

### Box 10 Adjuvant therapy in pancreatic cancer

- ▶ Adjuvant 5FU-based chemotherapy significantly improves survival.
- ▶ Adjuvant gemcitabine chemotherapy may also significantly improve survival.
- ▶ Adjuvant chemoradiation has not been shown to improve survival in the absence of maintenance chemotherapy.
- ▶ Adjuvant chemoradiotherapy and follow-on chemotherapy may not offer improved survival compared with chemotherapy alone—trial awaited.
- ▶ Neoadjuvant treatments should only be administered as part of a controlled clinical trial.

Adjuvant chemoradiotherapy has been used in the USA on the basis of a small randomised trial<sup>230–231</sup> as well as apparently improving survival as reported in a non-randomised series of patients,<sup>232–233</sup> but these results have not been confirmed in large randomised trials,<sup>223–224–234–235</sup> so the focus has moved to whether chemoradiotherapy and follow-on chemotherapy represents a better alternative than chemotherapy alone (table 7).<sup>223–224–230–231–234–236</sup> The results of meta-analysis using individual patient data reject the use of chemoradiation and provide powerful evidence for systemic chemotherapy.<sup>235</sup>

The RTOG 9704 trial<sup>236</sup> has recently reported median and 3-year survival rates. This study used background 5FU-based chemoradiotherapy together with pre- and post-chemoradiation systemic chemotherapy comprising either 5FU or gemcitabine. The original sample size was 330 patients, but this was increased to 518 patients to enable assessment of survival in patients with pancreatic head tumours. The results showed no difference in median survival or 3-year survival in all patients. There was, however, a significant improvement in survival with the gemcitabine-based treatment in patients who had tumours

**Table 3** Phase III trials of new agents in pancreatic cancer<sup>196–201</sup>

| Trial                                     | Patients (n) | Regimen  | Comments  |
|---|--------------|--|---|
| PA3 (Canada, USA) <sup>196</sup>          | 569          | Gemcitabine vs<br>Gemcitabine + erlotinib  | Median survival = 5.91 months; 1 year survival = 17%<br>Median survival = 6.37 months; 1 year survival = 24% (NS) Erlotinib = EGFR tyrosine kinase inhibitor (oral) |
| SWOG S0205 (USA) <sup>197</sup>           | 704          | Gemcitabine vs<br>Gemcitabine + cetuximab  | Active cetuximab = monoclonal antibody to EGFR  |
| CALGB 80303 (USA) <sup>198</sup>          | 590          | Gemcitabine vs<br>Gemcitabine + bevacizumab (Avastin)  | Closed (NS) bevacizumab = anti-VEGFR antibody   |
| Avita (Europe) <sup>199</sup>             | 600          | Gemcitabine + erlotinib vs<br>Gemcitabine + bevacizumab + erlotinib  | Closed prematurely  |
| GV1001 (Europe, Australia) <sup>200</sup> | 520          | Gemcitabine vs<br>GV1001 [+ GMCSF] + gemcitabine   | Active GV1001 = peptide vaccine targeting telomerase  |
| TeloVac (UK) <sup>201</sup>               | 1100         | Gemcitabine + capecitabine vs<br>Gemcitabine + capecitabine then<br>GV1001 [+ GMCSF] vs<br>Gemcitabine + capecitabine +<br>GV1001[+ GMCSF] | Active  |

EGFR, epidermal growth factor receptor; GMCSF, granulocyte monocyte colony-stimulating factor.

**Table 4** Indicators of resectability in pancreatic cancer

| Factors contraindicating resection                                       | Factors not contraindicating resection   |
|--|--|
| Liver, peritoneal or other metastasis                                    | Continuous invasion of duodenum, stomach or colon                                      |
| Uncertain whether distant lymph node metastasis influence prognosis      | Lymph node metastasis within the operative field                                       |
| Major venous encasement: >2 cm in length, >50% circumference involvement | Para-aortic lymph node involvement   |
| Superior mesenteric, coeliac or hepatic artery encasement                | Venous impingement or minimal invasion of superior mesenteric and hepatic portal veins |
| Severe comorbid illness  | Gastroduodenal artery encasement   |
| Cirrhosis with portal hypertension                                       | Age of patient   |

**Table 5** Randomised controlled trials comparing pylorus preserving and standard pancreatoduodenectomy<sup>213–215</sup>

| Study                                   | Type of resection                        | Patients (n) | Median survival (months) | Complications                     |
|---|--|--------------|--------------------------|-----------------------------------|
| Lin and Lin 2005 <sup>213</sup>         | Pylorus-preserving pancreatoduodenectomy | 14           | NS                       | Delayed gastric emptying (p<0.05) |
|   | Standard pancreatoduodenectomy           | 19           |                          |                                   |
| Tran <i>et al</i> 2004 <sup>214</sup>   | Pylorus-preserving pancreatoduodenectomy | 47           | 12                       | NS                                |
|   | Standard pancreatoduodenectomy           | 43           | 11 (NS)                  |                                   |
| Seiler <i>et al</i> 2005 <sup>215</sup> | Pylorus-preserving pancreatoduodenectomy | 37           | 19.2                     | NS                                |
|   | Standard pancreatoduodenectomy           | 43           | 18.2 (NS)                |                                   |

of the pancreatic head. These findings are in keeping with survival noted in the equivalent groups in the ESPAC-1 trial and do not show any advantage over chemotherapy alone.

The EORTC trial 40013 plans to recruit 538 patients with resectable pancreatic cancer and compare gemcitabine chemotherapy with gemcitabine followed by chemoradiotherapy. There is an initial phase II part to assess feasibility and toxicity. Neoadjuvant therapy has also been advocated to increase

resection rates, reduce positive resection margins and for the early treatment of micrometastatic disease, but at present there is little evidence to support this approach and randomised trials are lacking.<sup>187 204</sup>

**CONCLUSIONS**

Pancreatic cancer is a formidable disease to diagnose and treat. Surgical approaches have become more standardised and are

**Table 6** Adjuvant systemic chemotherapy: randomised controlled trials<sup>223–228</sup>

| Series   | Period    | Patients (n) | Regimen       | Median survival (months) | Actuarial survival (%) |         |         |   |
|--|-----------|--------------|---------------|--------------------------|------------------------|---------|---------|---|
|  |           |              |               |                          | 1 Year                 | 2 Years | 3 Years | 5 Years   |
| Bakkevdol <i>et al</i> <sup>226</sup>                    | 1984–7    | 61           | 5FU/DOX/MMC   | 23                       | 70                     |         | 27      | 4   |
|  |           | 31           | Observation   | 11 (p=0.02)              | 45                     |         | 30      | 8   |
| Takada <i>et al</i> <sup>227</sup> (pancreas only)       | 1986–92   | 81           | MMC/5FU       |                          |                        |         |         | 11.5  |
|  | 1986–92   | 77           | Observation   |                          |                        |         |         | 18 (NS)   |
| Kosuge <i>et al</i> <sup>228</sup>                       | 1992–2000 | 45           | 5FU/cisplatin | 12.5                     |                        |         |         | 26.4  |
|  |           | 44           | Observation   | 15.8                     |                        |         |         | 14.9 (NS)   |
| ESPAC-1 <sup>223</sup>                                   | 1994–2000 | 238          | 5FU/FA        | 19.7                     |                        |         |         | Hazard ratio = 0.66 (95% CI 0.52 to 0.83) (p=0.005) |
| Interim—all patients                                     |           | 253          | –             | 14.0 (p=0.005)           |                        |         |         |   |
| ESPAC-1 <sup>224</sup> Final—individual treatment groups | 1994–2000 | 75           | 5FU/FA        | 21.6                     |                        | 44.0    |         | 29.0  |
|  |           | 69           | Observation   | 16.9                     |                        | 38.7    |         | 10.7 (p=0.009)                                      |
| Oettle <i>et al</i> <sup>225</sup>                       | 1998–2004 | 179          | Gemcitabine   | 22.1                     |                        |         | 34      | 22.5  |
|  |           | 177          | Observation   | 20.2                     |                        |         | 20.5    | 11.5 (p=0.06)                                       |

DOX, doxorubicin; FA, folinic acid; 5FU, 5- fluorouracil; MMC, mitomycin.

**Table 7** Adjuvant chemoradiotherapy: randomised controlled trials<sup>223 224 230 231 234 236</sup>

| Series  | Period    | Patients (n) | Regimen                                    | Median survival (months) | Actuarial survival (%) |         |         |  |
|---|-----------|--------------|--|--------------------------|------------------------|---------|---------|--|
|   |           |              |  |                          | 1 Year                 | 2 Years | 3 Years | 5 Years  |
| GITSG 9173 <sup>230,231</sup>                               | 1987–95   | 21           | 40 Gy/5FU, with                            | 21                       |                        | 43      |         | 19   |
|   |           | 22           | 5FU maintenance                            | 10.9                     |                        | 18      |         | 5  |
|   |           | –            | –  | (p=0.03)                 |                        |         |         |  |
| Klinkenbijl <i>et al</i> <sup>234</sup>                     | 1987–95   | 110          | 40 Gy/FU                                   | 24.5                     | 41                     |         |         | 10   |
|   |           | 108          | –  | 19                       | 51                     |         |         | 20   |
|   |           |              |  | (p=0.208)                |                        |         |         |  |
| ESPAC-1 <sup>223</sup>                                      | 1994–2000 | 175          | 40 Gy/5FU                                  | 15.5                     |                        |         |         |  |
| Interim results—all patients                                |           | 178          | ± 5FU/FA maintenance                       | 16.1                     |                        |         |         | (hazard ratio was 1.18 (95% CI 0.90 to 1.55)) (NS) |
| ESPAC-1 <sup>223</sup><br>Final—2×2 factorial               | 1994–2000 | 145          | 40 Gy/5FU                                  | 15.9                     |                        | 29      |         | 10   |
|   |           | 144          | ± 5FU/FA maintenance                       | 14.8                     |                        | 41      |         | 20 (NS)  |
|   |           |              |  | (p=0.05)                 |                        |         |         |  |
| ESPAC-1 <sup>224</sup><br>Final—individual treatment groups | 1994–2000 | 69           | Observation                                | 16.9                     |                        | 38.7    |         | 10.7   |
|   |           | 73           | 40 Gy/5FU                                  | 13.9                     |                        | 21.7    |         | 7.3  |
|   |           | 75           | 5FU/FA                                     | 21.6                     |                        | 44.0    |         | 29.0   |
|   |           | 72           | 40 Gy/5FU + 5FU/FA maintenance             | 19.9                     |                        | 35.5    |         | 13.2   |
|   |           |              |  |                          |                        |         |         | (p=0.009)  |
| RT0G 9704 <sup>236</sup>                                    | 1998–2002 | 221          | Gem before CRT, 50.4 Gy/5FU, gem after CRT |                          |                        |         |         |  |
| All patients = 538  |           | 221          | 5FU before CRT, 50.4 Gy/5FU, 5FU after CRT | (p=0.15)                 |                        |         |         |  |
| Eligible = 442  |           | 187          | Gem before CRT, 50.4 Gy/5FU, gem after CRT | 20.6                     |                        |         | 32      |  |
| Head of pancreas only—eligible = 381                        |           | 194          | 5FU before CRT, 50.4 Gy/5FU, 5FU after CRT | 16.9                     |                        |         | 21      |  |
|   |           |              |  | (p=0.033)                |                        |         |         |  |

CRT, chemoradiation; FA, folinic acid; 5FU, 5-fluorouracil; Gem, gemcitabine.

safer, with much improvement in both morbidity and mortality in specialised centres. Diagnosis has improved using conventional imaging methods, and appropriate treatment decisions can be made because of these improvements. Palliative treatment is improving, including the use of endoscopic stent placement with better but less than effective pain relief, and pancreatic enzyme supplementation. Chemotherapy regimens can prolong survival in patients with advanced disease without reducing their quality of life. At present only pancreatic resection can improve survival significantly. A further improvement in survival is achievable with adjuvant chemotherapy but not chemoradiotherapy. The molecular mechanisms responsible for pancreatic cancer point to earlier diagnosis and targeted treatments, using new genetic and biological approaches. Pancreatic cancer surgery can only be performed within a regional pancreas cancer. This is now a very encouraging phase in the diagnosis and treatment of pancreatic cancer. The information and resources now available can result in a reasoned approach to the treatment of patients with pancreatic cancer to ensure the best outcome with an optimum quality of life.

#### ACKNOWLEDGEMENTS

We gratefully acknowledge the provision of figures from staff at the Royal Liverpool University Hospital Trust: pathology figures are kindly supplied by Dr Fiona Campbell, consultant histopathologist, Department of Pathology and also Dr Jutta Luetgtes, Klinikum Saarbrücken, Germany; radiology figures are kindly supplied by Dr Jonathan Evans, consultant radiologist, Department of Radiology; and EUS figures are kindly supplied by Dr Martin Lombard, consultant gastroenterologist, Department of Gastroenterology.

#### Authors' affiliations

Paula Ghaneh, Eithne Costello, John P Neoptolemos, Division of Surgery and Oncology, University of Liverpool, UK

Funding: Cancer Research UK, CORE and EU Biomed Programmes 5 and 6.

Conflict of Interest: None.

#### REFERENCES

- Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. *Eur J Cancer* 2001;**37**(Suppl 8):4–66.
- CancerStats. <http://info.cancerresearchuk.org/cancerstats/> (accessed 17 May 2007).
- Jemal A, Siegel R, Ward E, *et al*. Cancer statistics, 2007. *CA Cancer J Clin* 2007;**57**:43–66.
- Alderson D, Johnson CD, Neoptolemos JP, *et al*. Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas. *Gut* 2005;**54**(Suppl 5):v1–16.
- Neoptolemos JP, Russell RC, Bramhall S, *et al*. Low mortality following resection for pancreatic and periampullary tumours in 1026 patients: UK survey of specialist pancreatic units. UK Pancreatic Cancer Group. *Br J Surg* 1997;**84**:1370–6.
- Maitra A, Fukushima N, Takaori K, *et al*. Precursors to invasive pancreatic cancer. *Adv Anat Pathol* 2005;**12**:81–91.
- Hruban RH, Adsay NV, Albores-Saavedra J, *et al*. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. *Am J Surg Pathol* 2001;**25**:579–86.
- Hruban RH, Takaori K, Klimstra DS, *et al*. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. *Am J Surg Pathol* 2004;**28**:977–87.
- Hruban RH, Goggins M, Parsons J, *et al*. Progression model for pancreatic cancer. *Clin Cancer Res* 2000;**6**:2969–72.
- Almoguera C, Shibata D, Forrester K, *et al*. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. *Cell* 1988;**53**:549–54.
- Hruban RH, van Mansfeld AD, Offerhaus GJ, *et al*. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a

- combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. *Am J Pathol* 1993;**143**:545–54.
- 12 **Malumbres M**, Barbacid M. RAS oncogenes: the first 30 years. *Nat Rev Cancer* 2003;**3**:459–65.
  - 13 **Yanagisawa A**, Ohtake K, Ohashi K, et al. Frequent c-Ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation. *Cancer Res* 1993;**53**:953–6.
  - 14 **Tada M**, Ohashi M, Shiratori Y, et al. Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. *Gastroenterology* 1996;**110**:227–31.
  - 15 **Luttges J**, Schlehe B, Menke MA, et al. The K-ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium. *Cancer* 1999;**85**:1703–10.
  - 16 **Xiong HQ**. Molecular targeting therapy for pancreatic cancer. *Cancer Chemother Pharmacol* 2004;**54**(Suppl 1):S69–77.
  - 17 **Ko AH**, Tempero MA. Systemic therapy for pancreatic cancer. *Semin Radiat Oncol* 2005;**15**:245–53.
  - 18 **Van Cutsem E**, van de Velde H, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. *J Clin Oncol* 2004;**22**:1430–8.
  - 19 **Brummelkamp TR**, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. *Cancer Cell* 2002;**2**:243–7.
  - 20 **Fleming JB**, Shen GL, Holloway SE, et al. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy. *Mol Cancer Res* 2005;**3**:413–23.
  - 21 **Brunner TB**, Cengel KA, Hahn SM, et al. Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras. *Cancer Res* 2005;**65**:8433–41.
  - 22 **Kane RC**, Farrell AT, Saber H, et al. Sorafenib for the treatment of advanced renal cell carcinoma. *Clin Cancer Res* 2006;**12**:7271–8.
  - 23 **Wallace JA**, Locker G, Natam S, et al. Sorafenib (S) plus gemcitabine (G) for advanced pancreatic cancer (PC): a phase II trial of the University of Chicago Phase II Consortium. *ASCO Gastrointestinal Cancers Symposium*. 2007: abstr 137J.
  - 24 **Korc M**, Chandrasekar B, Yamanaka Y, et al. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. *J Clin Invest* 1992;**90**:1352–60.
  - 25 **Yamanaka Y**, Friess H, Kobrin MS, et al. Overexpression of HER2/neu oncogene in human pancreatic carcinoma. *Hum Pathol* 1993;**24**:1127–34.
  - 26 **Friess H**, Yamanaka Y, Kobrin MS, et al. Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression. *Clin Cancer Res* 1995;**1**:1413–20.
  - 27 **Barton CM**, Hall PA, Hughes CM, et al. Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer. *J Pathol* 1991;**163**:111–6.
  - 28 **Marshall J**. Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. *Cancer* 2006;**107**:1207–18.
  - 29 **Xiong HQ**, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. *J Clin Oncol* 2004;**22**:2610–6.
  - 30 **Anonymous**. SWOG S0502: phase III randomized study of gemcitabine with versus without cetuximab as first-line therapy in patients with locally advanced unresectable or metastatic adenocarcinoma of the pancreas. *Clin Adv Hematol Oncol* 2004;**2**:201–52.
  - 31 **Tang PA**, Tsao MS, Moore MJ. A review of erlotinib and its clinical use. *Expert Opin Pharmacother* 2006;**7**:177–93.
  - 32 **Ozawa F**, Friess H, Tempia-Caliera A, et al. Growth factors and their receptors in pancreatic cancer. *Teratog Carcinog Mutagen* 2001;**21**:27–44.
  - 33 **Seo Y**, Baba H, Fukuda T, et al. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. *Cancer* 2000;**88**:2239–45.
  - 34 **Kindler HL**, Friberg G, Singh DA, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. *J Clin Oncol* 2005;**23**:8033–40.
  - 35 **Kindler HL**, Niedzwiecki D, Hollis D, et al. Double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB) 80303. *ASCO Gastrointestinal Cancers Symposium*. 2007: abstr 108J.
  - 36 **de Jonge MJ**, Verweij J. Multiple targeted tyrosine kinase inhibition in the clinic: all for one or one for all? *Eur J Cancer* 2006;**42**:1351–6.
  - 37 **Cheng JQ**, Ruggeri B, Klein WM, et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. *Proc Natl Acad Sci USA* 1996;**93**:3636–41.R.
  - 38 **Ruggeri BA**, Huang L, Wood M, et al. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. *Mol Carcinog* 1998;**21**:81–6.
  - 39 **Altomare DA**, Tanno S, De Rienzo A, et al. Frequent activation of AKT2 kinase in human pancreatic carcinomas. *J Cell Biochem* 2003;**88**:470–6.
  - 40 **Schlieman MG**, Fahy BN, Ramsamooj R, et al. Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. *Br J Cancer* 2003;**89**:2110–5.
  - 41 **Schmelzle T**, Hall MN. TOR, a central controller of cell growth. *Cell* 2000;**103**:253–62.
  - 42 **Shah SA**, Potter MW, Ricciardi R, et al. FRAP-p70s6K signaling is required for pancreatic cancer cell proliferation. *J Surg Res* 2001;**97**:123–30.
  - 43 **Grewe M**, Gansauge F, Schmid RM, et al. Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. *Cancer Res* 1999;**59**:3581–7.
  - 44 **Asano T**, Yao Y, Zhu J, et al. The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation. *Biochem Biophys Res Commun* 2005;**331**:295–302.
  - 45 **Ito D**, Fujimoto K, Mori T, et al. In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. *Int J Cancer* 2006;**118**:2337–43.
  - 46 **Fernandez-Zapico ME**, Urrutia R. Molecular pathogenesis of pancreatic carcinogenesis. *Drug Discovery Today: Disease Mechanisms* 2004;**1**:247–52.
  - 47 **Ryan DP**, O'Neil BH, Supko JG, et al. A phase I study of bortezomib plus irinotecan in patients with advanced solid tumors. *Cancer* 2006;**107**:2688–97.
  - 48 **Sherr CJ**. Principles of tumor suppression. *Cell* 2004;**116**:235–46.
  - 49 **Liu H**, Dibling B, Spike B, et al. New roles for the RB tumor suppressor protein. *Curr Opin Genet Dev* 2004;**14**:55–64.
  - 50 **Rozenblum E**, Schutte M, Goggins M, et al. Tumor-suppressive pathways in pancreatic carcinoma. *Cancer Res* 1997;**57**:1731–4.
  - 51 **Caldas C**, Hahn SA, da Costa LT, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. *Nat Genet* 1994;**8**:27–32.
  - 52 **Knudson AG Jr**. Retinoblastoma: a prototypic hereditary neoplasm. *Semin Oncol* 1978;**5**:57–60.
  - 53 **Sharpless NE**. INK4a/ARF: a multifunctional tumor suppressor locus. *Mutat Res* 2005;**576**:22–38.
  - 54 **Sherr CJ**. Divorcing ARF and p53: an unsettled case. *Nat Rev Cancer* 2006;**6**:663–73.
  - 55 **Bardeesy N**, DePinho RA. Pancreatic cancer biology and genetics. *Nat Rev Cancer* 2002;**2**:897–909.
  - 56 **Christopherou MA**, Ringshausen I, Finch AJ, et al. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. *Nature* 2006;**443**:214–7.
  - 57 **Hahn SA**, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. *Science* 1996;**271**:350–3.
  - 58 **Rane SG**, Lee JH, Lin HM. Transforming growth factor-beta pathway: role in pancreas development and pancreatic disease. *Cytokine Growth Factor Rev* 2006;**17**:107–19.
  - 59 **Schwartz-Waldhoff I**, Volpert OV, Bouck NP, et al. Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. *Proc Natl Acad Sci USA* 2000;**97**:9624–9.
  - 60 **Duda DG**, Sunamura M, Lefter LP, et al. Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells. *Oncogene* 2003;**22**:6857–64.
  - 61 **Zapatka M**, Zboralski D, Radacz Y, et al. Basement membrane component laminin-5 is a target of the tumor suppressor Smad4. *Oncogene* 2007;**25**:1417–27.
  - 62 **Bierie B**, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. *Nat Rev Cancer* 2006;**6**:506–20.
  - 63 **Friess H**, Yamanaka Y, Buchler M, et al. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. *Gastroenterology* 1993;**105**:1846–56.
  - 64 **Levy L**, Hill CS. Smad4 dependency defines two classes of transforming growth factor [beta] (TGF-[beta]) target genes and distinguishes TGF-[beta]-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses. *Mol Cell Biol* 2005;**25**:8108–25.
  - 65 **Leach SD**. Epithelial differentiation in pancreatic development and neoplasia: new niches for nestin and Notch. *J Clin Gastroenterol* 2005;**39**:S78–82.
  - 66 **Lomber G**, Fernandez-Zapico ME, Urrutia R. When developmental signaling pathways go wrong and their impact on pancreatic cancer development. *Curr Opin Gastroenterol* 2005;**21**:555–60.
  - 67 **Miyamoto Y**, Maitra A, Ghosh B, et al. Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. *Cancer Cell* 2003;**3**:565–76.
  - 68 **Rehman AO**, Wang CY. Notch signaling in the regulation of tumor angiogenesis. *Trends Cell Biol* 2006;**16**:293–300.
  - 69 **Taipale J**, Cooper MK, Maiti T, et al. Patched acts catalytically to suppress the activity of Smoothened. *Nature* 2002;**418**:892–7.
  - 70 **Thayer SP**, di Magliano MP, Heiser PW, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. *Nature* 2003;**425**:851–6.
  - 71 **Prasad NB**, Biankin AV, Fukushima N, et al. Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. *Cancer Res* 2005;**65**:1619–26.
  - 72 **Kayed H**, Kleeff J, Keleg S, et al. Indian hedgehog signaling pathway: expression and regulation in pancreatic cancer. *Int J Cancer* 2004;**110**:668–76.
  - 73 **Kayed H**, Kleeff J, Osman T, et al. Hedgehog signaling in the normal and diseased pancreas. *Pancreas* 2006;**32**:119–29.
  - 74 **Incardona JP**, Gaffield W, Kapur RP, et al. The teratogenic Veratrum alkaloid cyclopamine inhibits sonic hedgehog signal transduction. *Development* 1998;**125**:3553–62.
  - 75 **Chen JK**, Taipale J, Cooper MK, et al. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. *Genes Dev* 2002;**16**:2743–8.
  - 76 **Li C**, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. *Cancer Res* 2007;**67**:1030–7.



- 77 **Tan BT**, Park CY, Ailles LE, *et al.* The cancer stem cell hypothesis: a work in progress. *Lab Invest* 2006;**86**:1203-7.
- 78 **Mueller MM**, Fusenig NE. Friends or foes - bipolar effects of the tumour stroma in cancer. *Nat Rev Cancer* 2004;**4**:839-49.
- 79 **Chu GC**, Kimmelman AC, Hezel AF, *et al.* Stromal biology of pancreatic cancer. *J Cell Biochem*, 2007 Jan 31 [Epub ahead of print].
- 80 **Bramhall SR**, Rosemurgy A, Brown PD, for the Marimastat Pancreatic Cancer Study Group, *et al.* Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. *J Clin Oncol* 2001;**19**:3447-55.
- 81 **Bramhall SR**, Schulz J, Nemunaitis J, *et al.* A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. *Br J Cancer* 2002;**87**:161-7.
- 82 **Jones LE**, Humphreys MJ, Campbell F, *et al.* Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer: increased expression of matrix metalloproteinase-7 predicts poor survival. *Clin Cancer Res* 2004;**10**:2832-45.
- 83 **Hezel AF**, Kimmelman AC, Stanger BZ, *et al.* Genetics and biology of pancreatic ductal adenocarcinoma. *Genes Dev* 2006;**20**:1218-49.
- 84 **Eckel F**, Schneider G, Schmid RM. Pancreatic cancer: a review of recent advances. *Expert Opin Investig Drugs* 2006;**15**:1395-410.
- 85 **Hingorani SR**, Petricoin EF, Maitra A, *et al.* Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. *Cancer Cell* 2003;**4**:437-50.
- 86 **Hingorani SR**, Wang L, Multani AS, *et al.* Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. *Cancer Cell* 2005;**7**:469-83.
- 87 **Laheru D**, Jaffee EM. Immunotherapy for pancreatic cancer - science driving clinical progress. *Nat Rev Cancer* 2005;**5**:459-67.
- 88 **Bernhardt SL**, Gjertsen MK, Trachsel S, *et al.* Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. *Br J Cancer* 2006;**95**:1474-82.
- 89 **Coughlin SS**, Calle EE, Patel AV, *et al.* Predictors of pancreatic cancer mortality among a large cohort of United States adults. *Cancer Causes Control* 2000;**11**:915-23.
- 90 **Chari ST**, Leibson CL, Rabe KG, *et al.* Probability of pancreatic cancer following diabetes: a population-based study. *Gastroenterology* 2005;**129**:504-11.
- 91 **Malka D**, Hammel P, Maire F, *et al.* Risk of pancreatic adenocarcinoma in chronic pancreatitis. *Gut* 2002;**51**:849-52.
- 92 **Howes N**, Neoptolemos JP. Risk of pancreatic ductal adenocarcinoma in chronic pancreatitis. *Gut* 2002;**51**:765-6.
- 93 **Howes N**, Lerch MM, Greenhalf W, for the European Registry of Hereditary Pancreatitis and Pancreatic Cancer (EUROPAC), *et al.* Clinical and genetic characteristics of hereditary pancreatitis in Europe. *Clin Gastroenterol Hepatol* 2004;**2**:252-61.
- 94 **Vitone LJ**, Greenhalf W, McFaul CD, *et al.* The inherited genetics of pancreatic cancer and prospects for secondary screening. *Best Pract Res Clin Gastroenterol* 2006;**20**:253-83.
- 95 **Klein AP**, Brune KA, Petersen GM, *et al.* Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. *Cancer Res* 2004;**64**:2634-8.
- 96 **Nothlings U**, Wilkens LR, Murphy SP, *et al.* Meat and fat intake as risk factors for pancreatic cancer: The Multiethnic Cohort Study. *J Natl Cancer Inst* 2005;**97**:1458-65.
- 97 **Larsson SC**, Hakansson N, Giovannucci E, *et al.* Methionine and vitamin B6 intake and risk of pancreatic cancer: a prospective study of swedish women and men. *Gastroenterology* 2007;**132**:113-8.
- 98 **Larsson SC**, Hakansson N, Giovannucci E, *et al.* Folate intake and pancreatic cancer incidence: a prospective study of Swedish women and men. *J Natl Cancer Inst* 2006;**98**:407-13.
- 99 **Klein AP**, Beaty TH, Bailey-Wilson JE, *et al.* Evidence for a major gene influencing risk of pancreatic cancer. *Genet Epidemiol* 2002;**23**:133-49.
- 100 **McFaul CD**, Greenhalf W, Earl J, for the German national Case Collection for Familial Pancreatic Cancer (FaPaCa), *et al.* Anticipation in familial pancreatic cancer. *Gut* 2006;**55**:252-8.
- 101 **Hahn SA**, Greenhalf B, Ellis I, *et al.* BRCA2 germ line mutations in familial pancreatic carcinoma. *J Natl Cancer Inst* 2003;**95**:214-21.
- 102 **Pogue-Geile KL**, Chen R, Bronner MP, *et al.* Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. *PLoS Med* 2006;**3**:e516.
- 103 **Eberle MA**, Pfutzer R, Pogue-Geile KL, *et al.* A new susceptibility locus for autosomal dominant pancreatic cancer maps to chromosome 4q32-34. *Am J Hum Genet* 2002:1044-8.
- 104 **Earl J**, Yan L, Vitone LJ, *et al.* Evaluation of the 4q32-34 locus in European familial pancreatic cancer. *Cancer Epidemiol Biomarkers Prev* 2006;**15**:1948-55.
- 105 **Slater EP**, Amrillaeva V, Fendrich V, *et al.* Absence of the palladin P239S mutation in European pancreatic cancer families. *PLoS Med* 2007;**3**:e516.
- 106 **Duell EJ**, Holly EA, Bracci PM, *et al.* A population-based, case-control study of polymorphisms in carcinogen-metabolizing genes, smoking, and pancreatic adenocarcinoma risk. *J Natl Cancer Inst* 2002;**94**:297-306.
- 107 **Bartsch H**, Malaveille C, Lowenfels AB, *et al.* Genetic polymorphism of N-acetyltransferases, glutathione S-transferase M1 and NAD. *Eur J Cancer Prev* 1998;**7**:215-23.
- 108 **Ockenga J**, Vogel A, Teich N, *et al.* UDP glucuronosyltransferase (UGT1A7) gene polymorphisms increase the risk of chronic pancreatitis and pancreatic cancer. *Gastroenterology* 2003;**124**:1802-8.
- 109 **Vasen HF**, Gruis NA, Frants RR, *et al.* Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). *Int J Cancer* 2000;**87**:809-11.
- 110 **Lal G**, Liu G, Schmocker B, *et al.* Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. *Cancer Res* 2000;**60**:409-16.
- 111 **Rogers CD**, van der Heijden MS, Brune K, *et al.* The genetics of FANCC and FANCG in familial pancreatic cancer. *Cancer Biol Ther* 2004;**3**:167-9.
- 112 **Su GH**, Hruban RH, Bansal RK, *et al.* Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. *Am J Pathol* 1999;**154**:1835-40.
- 113 **Hammel PR**, Vilgrain V, Terris B, *et al.* Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d'Etude de la Maladie de von Hippel-Lindau. *Gastroenterology* 2000;**119**:1087-95.
- 114 **Narita T**, Takagi K. Ataxia-telangiectasia with dysgerminoma of right ovary, papillary carcinoma of thyroid, and adenocarcinoma of pancreas. *Cancer* 1984;**54**:1113-6.
- 115 **Birch JM**, Alston RD, McNally RJ, *et al.* Relative frequency and morphology of cancers in carriers of germline TP53 mutations. *Oncogene* 2001;**20**:4621-8.
- 116 **McWilliams R**, Highsmith WE, Rabe KG, *et al.* Cystic fibrosis transmembrane regulator gene carrier status is a risk factor for young onset pancreatic adenocarcinoma. *Gut* 2005;**54**:1661-2.
- 117 **Seket B**, Saurin JC, Scaozec JY, *et al.* Pancreatic acinar cell carcinoma in a patient with familial adenomatous polyposis. *Gastroenterol Clin Biol* 2003;**27**:818-20.
- 118 **Sudo T**, Murakami Y, Uemura K, *et al.* Development of an intraductal papillary-mucinous neoplasm of the pancreas in a patient with familial adenomatous polyposis. *Pancreas* 2005;**31**:428-9.
- 119 **Banville N**, Geraghty R, Fox E, *et al.* Medullary carcinoma of the pancreas in a man with hereditary nonpolyposis colorectal cancer due to a mutation of the MSH2 mismatch repair gene. *Hum Pathol* 2006;**37**:1498-502.
- 120 **Grützmann R**, McFaul C, Bartsch DK, *et al.* No evidence for germline mutations of the LKB1/STK11 gene in familial pancreatic carcinoma. *Cancer Lett* 2004;**214**:63-8.
- 121 **Bartsch DK**, Fendrich V, Slater EP, *et al.* RNASEL germline variants are associated with pancreatic cancer. *Int J Cancer* 2005;**117**:718-22.
- 122 **Canto MI**, Goggins M, Yeo CJ, *et al.* Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. *Clin Gastroenterol Hepatol* 2004;**2**:606-21.
- 123 **Yan L**, McFaul C, Howes N, *et al.* Molecular analysis to detect pancreatic ductal adenocarcinoma in high risk groups. *Gastroenterology* 2005;**128**:2124-30.
- 124 **Latchford A**, Greenhalf W, Vitone LJ, *et al.* Peutz-Jeghers syndrome and screening for pancreatic cancer. *Br J Surg* 2006;**93**:1446-55.
- 125 **Klöppel G**, Solcia E, Longnecker DS, *et al.* *World Health Organization international histological typing of tumors of the exocrine pancreas*. Berlin: Springer, 1996:1-61.
- 126 **Han SS**, Jang JY, Kim SW, *et al.* Analysis of long-term survivors after surgical resection for pancreatic cancer. *Pancreas* 2006;**32**:271-5.
- 127 **Carboni F**, Lepiane P, Santoro R, *et al.* Cystic pancreatic neoplasms: 12-year surgical experience. *J Exp Clin Cancer Res* 2006;**25**:167-75.
- 128 **Takahashi H**, Nakamori S, Nakahira S, *et al.* Surgical outcomes of noninvasive and minimally invasive intraductal papillary-mucinous neoplasms of the pancreas. *Ann Surg Oncol* 2006;**13**:955-60.
- 129 **Holen KD**, Klimstra DS, Hummer A, *et al.* Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors. *J Clin Oncol* 2002;**20**:4673-8.
- 130 **Seo HE**, Lee MK, Lee YD, *et al.* Solid-pseudopapillary tumor of the pancreas. *J Clin Gastroenterol* 2006;**40**:919-22.
- 131 **Dhebi AR**, Connor S, Campbell F, *et al.* Diagnosis, treatment and outcome of pancreatoblastoma. *Pancreatol* 2004;**4**:441-51.
- 132 Sobin KL, Wittekind C, eds. *TNM classification of malignant tumours*. 6th edn. New York: Wiley-Liss, 2002.
- 133 **Royal College of Pathologists**. *Standards and minimum datasets for reporting cancers. Minimum dataset for histopathological reporting of pancreatic, ampulla of Vater and bile duct carcinoma*. London: Royal College of Pathologists, 2002.
- 134 **Buchholz M**, Kestler HA, Bauer A, *et al.* Specialized DNA arrays for the differentiation of pancreatic tumors. *Clin Cancer Res* 2005;**11**:8048-54.
- 135 **Butturini G**, Stocken DD, Wente MN, on behalf of the Pancreatic Cancer Meta-analysis Group, *et al.* The influence of resection margins and treatment on survival for patients with pancreatic cancer within a meta-analysis of randomized controlled trials. *Arch Surg*, (in press).
- 136 **Neoptolemos JP**, Stocken DD, Dunn JA, for the members of the European Study Group for Pancreatic Cancer (ESPAC), *et al.* Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy within the ESPAC-1 randomized controlled trial. *Ann Surg* 2001;**234**:758-68.
- 137 **Neoptolemos JP**, Greenhalf W. Increasing survival rates for pancreatic cancer by earlier identification. *Nat Clin Pract Oncol* 2006;**3**:346-7.
- 138 **Neoptolemos JP**. Is endoscopic ultrasonography superior to multidetector CT for assessing pancreatic cancer? *Nat Clin Pract Oncol* 2005;**2**:78-9.
- 139 **DeWitt J**, Devereaux BM, Lehman GA, *et al.* Comparison of endoscopic ultrasound and computed tomography for the preoperative evaluation of

- pancreatic cancer: a systematic review. *Clin Gastroenterol Hepatol* 2006;**4**:717–25.
- 140 **Ghaneh P**, Magee C, Neoptolemos JP. Pancreatic cancer. In: Williams C, eds. *Evidence-based oncology*. London: BMJ Books, 2003:247–72.
- 141 **Ziske C**, Schlie C, Gorschluter M, et al. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. *Br J Cancer* 2003;**89**:1413–7.
- 142 **Ko AH**, Hwang J, Venook AP, et al. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. *Br J Cancer* 2005;**93**:195–9.
- 143 **Louhimo J**, Alfthan H, Stenman UH, et al. Serum HCG beta and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer. *Oncology* 2004;**66**:126–31.
- 144 **Koopmann J**, Fedarko NS, Jain A, et al. Evaluation of osteopontin as a biomarker for pancreatic adenocarcinoma. *Cancer Epidemiol Biomarkers Prev* 2004;**13**:487–91.
- 145 **Takehara A**, Eguchi H, Ohigashi H, et al. Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4. *Cancer Sci* 2006;**97**:1191–7.
- 146 **Ozkan H**, Akar T, Koklu S, et al. Significance of serum receptor-binding cancer antigen (RCAS1) in pancreatic cancer and benign pancreatobiliary diseases. *Pancreatol* 2006;**6**:268–72.
- 147 **Koopmann J**, Rosenzweig CN, Zhang Z, et al. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. *Clin Cancer Res* 2006;**12**:442–6.
- 148 **Koomen JM**, Shih LN, Coombes KR, et al. Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. *Clin Cancer Res* 2005;**11**:110–8.
- 149 **Honda K**, Hayashida Y, Umaki T, et al. Possible detection of pancreatic cancer by plasma protein profiling. *Cancer Res* 2005;**5**:10613–22.
- 150 **Zhao J**, Simeone DM, Heidt D, et al. Comparative serum glycoproteomics using lectin selected sialic acid glycoproteins with mass spectrometric analysis: application to pancreatic cancer serum. *J Proteome Res* 2006;**5**:1792–802.
- 151 **Minniti S**, Bruno C, Biasutti C, et al. Sonography versus helical CT in identification and staging of pancreatic ductal adenocarcinoma. *J Clin Ultrasound* 2003;**31**:175–82.
- 152 **Catalano C**, Laghi A, Fraioli F, et al. Pancreatic carcinoma: the role of high-resolution multislice spiral CT in the diagnosis and assessment of resectability. *Eur Radiol* 2003;**13**:149–56.
- 153 **Phoa SS**, Tillemann EH, van Delden OM, et al. Value of CT criteria in predicting survival in patients with potentially resectable pancreatic head carcinoma. *J Surg Oncol* 2005;**91**:33–40.
- 154 **Roche CJ**, Hughes ML, Garvey CJ, et al. CT and pathologic assessment of prospective nodal staging in patients with ductal adenocarcinoma of the head of the pancreas. *AJR Am J Roentgenol* 2003;**180**:475–80.
- 155 **Hanninen EL**, Ricke J, Amthauer H, et al. Magnetic resonance cholangiopancreatography: image quality, ductal morphology, and value of additional T2- and T1-weighted sequences for the assessment of suspected pancreatic cancer. *Acta Radiol* 2005;**46**:117–25.
- 156 **Hanninen E**, Sehoul J, Hach C, et al. Prospective evaluation of pancreatic tumours: accuracy of MR imaging with MR cholangiopancreatography and MR angiography. *Radiology* 2002;**224**:34–41.
- 157 **Lytars D**, Connor S, Bosonnet L, et al. Positron emission tomography does not add to computed tomography for the diagnosis and staging of pancreatic cancer. *Dig Surg*. 2005;**22**: 55–61; discussion 62).
- 158 **Lemke AJ**, Niehues SM, Hosten N, et al. Retrospective digital image fusion of multidetector CT and 18F-FDG PET: clinical value in pancreatic lesions—a prospective study with 104 patients. *J Nucl Med* 2004;**45**:1279–86.
- 159 **Cho SG**, Lee DH, Lee KY, et al. Differentiation of chronic focal pancreatitis from pancreatic carcinoma by in vivo proton magnetic resonance spectroscopy. *J Comput Assist Tomogr* 2005;**29**:163–9.
- 160 **Agarwal B**, Abu-Hamda E, Molke KL, et al. Endoscopic ultrasound-guided fine needle aspiration and multidetector spiral CT in the diagnosis of pancreatic cancer. *Am J Gastroenterol* 2004;**99**:844–50.
- 161 **Sewnath ME**, Karsten TM, Prins MH, et al. A meta-analysis on the efficacy of preoperative biliary drainage for tumors causing obstructive jaundice. *Ann Surg* 2002;**236**:17–27.
- 162 **Kosugi C**, Furuse J, Ishii H. Needle tract implantation of hepatocellular carcinoma and pancreatic carcinoma after ultrasound-guided percutaneous puncture: clinical and pathologic characteristics and the treatment of needle tract implantation. *World J Surg* 2004;**28**:29–32.
- 163 **Raut CP**, Grau AM, Staerckel GA, et al. Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration in patients with presumed pancreatic cancer. *J Gastrointest Surg* 2003;**7**:118–26.
- 164 **Micames C**, Jowell PS, White R. Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA. *Gastrointest Endosc* 2003;**58**:690–5.
- 165 **Wittmann J**, Kocjan G, Sgouras SN, et al. Endoscopic ultrasound-guided tissue sampling by combined fine needle aspiration and trucut needle biopsy: a prospective study. *Cytopathology* 2006;**17**:27–33.
- 166 **Doran HE**, Bosonnet L, Connor S, et al. Laparoscopy and laparoscopic ultrasound in the evaluation of pancreatic and periampullary tumours. *Dig Surg* 2004;**21**:305–13.
- 167 **Connor S**, Bosonnet L, Alexakis N, et al. Serum CA19-9 measurement increases the effectiveness of staging laparoscopy in patients with suspected pancreatic malignancy. *Dig Surg* 2005;**22**:80–5.
- 168 **Longnecker DS**, Adler G, Hruban RH, et al. Intraductal papillary-mucinous neoplasms of the pancreas. In: Hamilton SR, Aaltonen LA, eds. *World Health Organization classification of tumors. Pathology and genetics of tumors of the digestive system*. Lyon: IARC Press, 2000:237–41.
- 169 **Tanaka M**, Chari S, Adsay V, for the International Association of Pancreatology, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. *Pancreatol* 2006;**6**:17–32.
- 170 **Murakami Y**, Uemura K, Ohge H, et al. Intraductal papillary-mucinous neoplasms and mucinous cystic neoplasms of the pancreas differentiated by ovarian-type stroma. *Surgery* 2006;**140**:448–53.
- 171 **Serikawa M**, Sasaki T, Fujimoto Y, et al. Management of intraductal papillary-mucinous neoplasm of the pancreas: treatment strategy based on morphologic classification. *J Clin Gastroenterol* 2006;**40**:856–62.
- 172 **Levy P**, Jouannaud V, O'Toole D, et al. Natural history of intraductal papillary mucinous tumors of the pancreas: actuarial risk of malignancy. *Clin Gastroenterol Hepatol*, 2006 Apr, **4**:460–8.
- 173 **Eguchi H**, Ishikawa O, Ohigashi H, et al. Patients with pancreatic intraductal papillary mucinous neoplasms are at high risk of colorectal cancer development. *Surgery* 2006;**139**:749–54.
- 174 **Choi MG**, Kim SW, Han SS, et al. High incidence of extrapancreatic neoplasms in patients with intraductal papillary mucinous neoplasms. *Arch Surg*. 2006;**141**: 51–6; discussion 56).
- 175 **Tada M**, Kawabe T, Arizumi M, et al. Pancreatic cancer in patients with pancreatic cystic lesions: a prospective study in 197 patients. *Clin Gastroenterol Hepatol* 2006;**4**:1265–70.
- 176 **Salvia R**, Crippa S, Falconi M, et al. Branch-duct intraductal papillary mucinous neoplasms of the pancreas: to operate or not to operate? Results of a prospective protocol on the management of 109 consecutive patients. *Gut* Nov 24; [Epub ahead of print]..
- 177 **Rykowski JJ**, Hilgier M. Efficacy of neurolytic celiac plexus block in varying locations of pancreatic cancer: influence on pain relief. *Anesthesiology* 2000;**92**:347–54.
- 178 **Wong GY**, Schroeder DR, Carns PE, et al. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. *JAMA* 2004;**291**:1092–9.
- 179 **Suleyman Ozyalcin N**, Talu GK, Camlica H, et al. Efficacy of coeliac plexus and splanchnic nerve blockades in body and tail located pancreatic cancer pain. *Eur J Pain* 2004;**8**:539–45.
- 180 **Leksowski K**. Thoracoscopic splanchnicectomy for control of intractable pain due to advanced pancreatic cancer. *Surg Endosc* 2001;**15**:129–31.
- 181 **Bruno MJ**, Haverkort EB, Tijssen GP, et al. Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region. *Gut* 1998;**42**:92–6.
- 182 **Prat F**, Chapat O, Ducot B, et al. Predictive factors for survival of patients with inoperable malignant distal biliary strictures: a practical management guideline. *Gut* 1998;**42**:76–80.
- 183 **Maire F**, Hammel P, Ponsot P, et al. Long-term outcome of biliary and duodenal stents in palliative treatment of patients with unresectable adenocarcinoma of the head of pancreas. *Am J Gastroenterol* 2006;**101**:735–42.
- 184 **Sohn TA**, Lillemoe KD, Cameron JL, et al. Surgical palliation of unresectable periampullary adenocarcinoma in the 1990s. *J Am Coll Surg* 1999;**188**:658–66.
- 185 **Kuriansky J**, Saenz A, Astudillo E, et al. Simultaneous laparoscopic biliary and retrocolic gastric bypass in patients with unresectable carcinoma of the pancreas. *Surg Endosc* 2000;**14**:179–81.
- 186 **Shore S**, Raraty MG, Ghaneh P, et al. Chemotherapy for pancreatic cancer. *Aliment Pharmacol Ther* 2003;**18**:1049–69.
- 187 **Neoptolemos JP**, Cunningham D, Friess H, et al. Adjuvant therapy in pancreatic cancer: historical and current perspectives. *Ann Oncol* 2003;**14**:675–92.
- 188 **Sultana A**, Tudur Smith C, Cunningham D, et al. Meta-analyses on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. *Br J Cancer* 2007;**96**:1183–90.
- 189 **Sultana A**, Tudur-Smith C, Cunningham D, et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. *J Clin Oncol* (in press).
- 190 **Burris HA 3rd**, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. *J Clin Oncol* 1997;**15**:2403–13.
- 191 **Cunningham D**, Chau I, Stocken D, et al. Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. *Eur J Cancer*, 2005;**3**(Suppl 4)..
- 192 **Herrmann R**, Bodoky G, Ruhstaller T, et al. Gemcitabine (G) plus capecitabine versus G alone in locally advanced or metastatic pancreatic cancer. A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG) [abstract]. *J Clin Oncol* 2005;**23**:310s.
- 193 **Hess V**, Salzberg M, Borner M, et al. Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial. *J Clin Oncol* 2003;**21**:66–8.
- 194 **Smith DB**, Neoptolemos JP. Capecitabine in carcinoma of the pancreas. *Expert Opin Pharmacother* 2006;**7**:1633–9.
- 195 **Chaufert B**, Mornex F, Bonnetain F, et al. Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non

- metastatic pancreatic cancer: a FFCD-SFRO study, *J Clin Oncol*, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006:4008.
- 196 **Moore MJ**, Goldstein D, Hamm J, *et al*. National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol* 2007;**25**:1960–6.
  - 197 **Southwest Oncology Group**. <http://www.swog.org/Visitors/ViewProtocolDetails.asp?ProtocolID=1933> (accessed 18 May 2007).
  - 198 **Genentech**. Phase III study of Avastin in advanced pancreatic cancer does not meet primary endpoint. <http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=9867> (accessed 18 May 2007).
  - 199 **Roche**. Clinical trial protocol registry and results database. <http://www.roche-trials.com/index.html> (accessed 18 May 2007).
  - 200 **National Cancer Institute**. GV1001 and gemcitabine in sequential combination to gemcitabine monotherapy in pancreatic cancer. <http://www.nci.nih.gov/search/ViewClinicalTrials.aspx?cdrid=500356&version=HealthProfessional&protocolsearchid=3027286> (accessed 18 May 2007).
  - 201 **National Cancer Institute**. Phase III randomized study of chemoimmunotherapy comprising gemcitabine hydrochloride and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer. <http://www.nci.nih.gov/search/ViewClinicalTrials.aspx?cdrid=528021&version=HealthProfessional&protocolsearchid=3027286> (accessed 18 May 2007).
  - 202 **Tseng JF**, Raut CP, Lee JE, *et al*. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. *J Gastrointest Surg* 2004;**8**:935–50.
  - 203 **Seitmacher U**, Langrehr JM, Husmann I, *et al*. Reconstruction of visceral arteries with homografts in excision of the pancreas. *Chirurg* 2004;**75**:1199–206.
  - 204 **Alexakis N**, Halloran C, Raraty M, *et al*. Current standards of surgery for pancreatic cancer. *Br J Surg* 2004;**91**:1410–27.
  - 205 **Birkmeyer JD**, Warshaw AL, Finlayson SR, *et al*. Relationship between hospital volume and late survival after pancreaticoduodenectomy. *Surgery* 1999;**126**:178–83.
  - 206 **Birkmeyer JD**, Siewers AE, Finlayson EV, *et al*. Hospital volume and surgical mortality in the United States. *N Engl J Med* 2002;**346**:1128–37.
  - 207 **Winter JM**, Cameron JL, Campbell KA, *et al*. Pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. *J Gastrointest Surg* 2006;**10**:1199–211.
  - 208 **Saleh MM**, Norregaard P, Jorgensen HL, *et al*. Preoperative endoscopic stent placement before pancreaticoduodenectomy: a meta-analysis of the effect on morbidity and mortality. *Gastrointest Endosc* 2002;**56**:529–34.
  - 209 **Imamura M**, Doi R, Imaizumi T, *et al*. A randomized multicenter trial comparing resection and radiochemotherapy for resectable locally invasive pancreatic cancer. *Surgery* 2004;**136**:1003–11.
  - 210 **Jones L**, Russell C, Mosca F, *et al*. Standard Kausch-Whipple pancreaticoduodenectomy. *Dig Surg* 1999;**16**:297–304.
  - 211 **McKay A**, Mackenzie S, Sutherland FR, *et al*. Meta-analysis of pancreaticojejunostomy versus pancreaticogastrostomy reconstruction after pancreaticoduodenectomy. *Br J Surg* 2006;**93**:929–36.
  - 212 **Winter JM**, Cameron JL, Campbell KA, *et al*. Does pancreatic duct stenting decrease the rate of pancreatic fistula following pancreaticoduodenectomy? Results of a prospective randomized trial. *J Gastrointest Surg* 2006;**10**:1280–90.
  - 213 **Lin PW**, Lin YJ. Prospective randomized comparison between pylorus-preserving and standard pancreaticoduodenectomy. *Br J Surg* 1999;**86**:603–607.
  - 214 **Tran K**, Smeenk H, van Eijck C, *et al*. Pylorus preserving pancreaticoduodenectomy versus standard Whipple procedure: a randomised, multi-centre study of 170 patients with pancreatic or periampullary tumours. *Ann Surg* 2004;**240**:738–45.
  - 215 **Seiler C**, Wagner M, Bachmann T, *et al*. Randomized prospective trial on pylorus preserving versus classic duodenopancreatectomy (Whipple): long-term results. *Br J Surg* 2005;**92**:547–56.
  - 216 **Pedrazzoli P**, DiCarlo V, Dionigi R, *et al*. Standard versus extended lymphadenectomy associated with pancreaticoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group. *Ann Surg* 1998;**228**:508–17.
  - 217 **Riall TS**, Cameron JL, Lillemo KD, *et al*. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma—part 3: update on 5-year survival. *J Gastrointest Surg* 2005;**9**:1191–204.
  - 218 **Farnell MB**, Pearson RK, Sarr MG, for the Pancreas Cancer Working Group, *et al*. A prospective randomized trial comparing standard pancreaticoduodenectomy with pancreaticoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. *Surgery* 2005;**138**:618–28.
  - 219 **Connor S**, Bosonnet L, Ghaneh P, *et al*. Survival of patients with periampullary carcinoma is predicted by lymph node 8a but not by lymph node 16b1 status. *Br J Surg* 2004;**91**:1592–9.
  - 220 **Muscari F**, Suc B, Kirzin S, for the French Associations for Surgical Research, *et al*. Risk factors for mortality and intra-abdominal complications after pancreaticoduodenectomy: multivariate analysis in 300 patients. *Surgery* 2006;**139**:591–8.
  - 221 **Connor S**, Alexakis N, Garden OJ, *et al*. Meta-analysis of the value of somatostatin and its analogues in reducing complications associated with pancreatic surgery. *Br J Surg* 2005;**92**:1059–67.
  - 222 **Hishinuma S**, Ogata Y, Tomikawa M, *et al*. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. *J Gastrointest Surg* 2006;**10**:511–8.
  - 223 **Neoptolemos JP**, Dunn JA, Stocken DD, for the European Study Group for Pancreatic Cancer, *et al*. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. *Lancet* 2001;**358**:1576–85.
  - 224 **Neoptolemos JP**, Stocken DD, Friess H, for the European Study Group for Pancreatic Cancer, *et al*. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. *N Engl J Med* 2004;**350**:1200–10.
  - 225 **Oettle H**, Post S, Neuhaus P, *et al*. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. *JAMA* 2007;**297**:267–77.
  - 226 **Bakkevoeld KE**, Arnesjo B, Dahl O, *et al*. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater - results of a controlled, prospective, randomised multicentre study. *Eur J Cancer* 1993;**29A**:698–703.
  - 227 **Takada T**, Amano H, Yasuda H, *et al*. Is postoperative adjuvant chemotherapy useful for gall-bladder carcinoma? *Cancer* 2002;**95**:1685.
  - 228 **Kosuge T**, Kiuchi T, Mukai K, for the Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer (JSAP), *et al*. A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. *Jpn J Clin Oncol* 2006;**36**:159–65.
  - 229 **Bassi C**, Stocken DD, Olah A, *et al*. The influence of surgical resection and post-operative complications on survival following adjuvant treatment for pancreatic cancer in the ESPAC-1 randomized controlled trial. *Dig Surg* 2005;**22**:353–63.
  - 230 **Kalser MH**, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. *Arch Surg* 1985;**120**:899–903.
  - 231 **Gastrointestinal Tumor Study Group**. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. *Cancer* 1987;**59**:2006–10.
  - 232 **Picozzi VJ**, Kozarek RA, Traverso LW. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. *Am J Surg* 2003;**185**:476–80.
  - 233 **Yeo CJ**, Abrams RA, Grochow LB, *et al*. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. *Ann Surg* 1997;**225**:621–33.
  - 234 **Klinkenbijl JH**, Jeekel J, Sahnoud T, *et al*. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. *Ann Surg* 1999;**230**:776–84.
  - 235 **Stocken DD**, Buchler MW, Dervenis C, for the Pancreatic Cancer Meta-analysis Group, *et al*. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. *Br J Cancer* 2005;**92**:1372–81.
  - 236 **Regine WF**, Winter KW, Abrams R, *et al*. RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma. *J Clin Oncol*, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No 18S (June 20 Supplement), 2006:4007.